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The extraction of dried bulbs of Crinum variabile and subsequent targeted fractionation led to the 
isolation of lycorine, 1,2-O,O-diacetyllycorine, 2-O-acetyllycorine, 1-O-acetyllycorine, a 
diastereomeric mixture of haemanthidine and 6-epihaemanthidine, bulbispermine and criwelline. 
HPLC-MS/MS analysis of the extract was carried out, providing information regarding other 
alkaloidal constituents of C. variabile. The isolation of lycorine, as well as a brief HPLC-MS/MS 
dereplication study was carried out on an extract of Crinum paludosum, allowing for the tentative 
identification of ten alkaloidal constituents therein, with five alkaloids remaining unidentified. A brief 
synthetic study was carried out on higginsianins A and B, resulting in the generation of some 
analogues thereof. These included acetylated analogues of both, as well as bromination products of 





Ekstraksie van gedroogde Crinum variabile blombolle en die daaropvolgende fraksionering het  
likorien, 1,2-di-O-asetiellikorien, 2-O-asetiellikorien, 1-O-asetiellikorien, ‘n mengsel van 
haemantidien en 6-epi-haemantidien, bulbespermien en kriwelien opgelewer. HPLC-MS/MS analise 
van die C. var. ekstrak het adisionele  informasie van ander alkaloïde tot gevolge gehad. Isolasie van 
likorien asook ‘n kort HPLC-MS/MS analise van ‘n ekstrak van Crinum paludosum het tot gevolg 
gehad dat tien alkaloïde tentatief geidentifiseer kon word met nog vyf wat nie geidentifiseer kon word 
nie. 
‘n Kort sintetise studie op higginsiansins A en B was uitgevoer en het gelei tot die isolasie van die 
geasetileerde higgginsiansins A en B, die gebromeerde analoog van higginsiansin A, die 
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6.1 Background on plant-based medicines 
6.1.1 Empirical use of plant-based treatments 
Since before our collective recollection, human societies have been in close contact with their 
environments, and have utilized the inherent value present in the natural resources therein. A practice 
that has been indispensable in this regard is the use of living organisms, particularly plants, for the 
treatment of diseases, injuries and ailments.1  
Determining the length of time for which humans have used plants as medicines is difficult, given 
that such practices predate written or illustrative records.2 In fact, it seems that the use of plants for 
health benefits is not limited to humans, but has been seen in other animal species, including monkeys 
and apes. Furthermore, it has been shown that humans and chimpanzees choose some of the same 
plant species to use as combatants against similar symptoms.3,4 This could suggest that such practices 
have evolutionary roots, and hints at a long history of close and intertwined interactions between our 
species and medicinally beneficial plants. Some archaeological evidence points towards the 
possibility that plants were cultivated for medicinal purposes over 60 000 years ago, as indicated by 
some discoveries in a Neanderthal burial site.5 This evidence is based on the presence of pollen in a 
Neanderthal grave, from 28 species of flowers. Seven of these species were known to possess 
medicinal qualities at the time of this discovery (1975), leading to the postulation that they were 
possibly used as such.5,6 There is also, however, the possibility that a rodent native to the area, known 
to store seeds and flowers, was responsible for their presence.6 Regardless of the possibility of 
contamination, however, the presence of the flowers does not prove their function as medicines. They 
could have simply formed part of the diet, as ancient medicines often originated from foods with 
beneficial health effects.6  
Regarding records of such plant uses; it seems as though medicines have been mentioned since the 
origin of written communications, in Mesopotamia and Egypt.6 The oldest known records - from 
Mesopotamia, and written in cuneiform on clay tablets - date back to about 1700 BC.6 Many, however 
were found to be copies of older texts, containing drug names dating back to 2000-3000 BC.6,7 These 
refer to several plant species, including Commiphora species (myrrh), Cupressus sempervirens 
(cyprus) and Papaver somniferum (poppy) juice,7 though Sneader warns that the identification of the 
plants in the texts is not reliable.6 Drugs derived from the species, vide supra, are still in use today.  
Ancient Egyptian medicine is also represented in written records, referred to as the papyri (sing. 




of the medical papyri is known as the Ebers papyrus, and dates back to about 1530 BC.8 It lists over 
800 prescriptions,6 most of which concern plant-based treatments.7 Like the cuneiform tablets, the 
Egyptian papyri contain elements dating back further than the document itself, as far as the fourth 
millennium BC.6 
These early works intertwined the ideas of magic and/or religion with that of medicine, including 
rituals and incantations in treatment descriptions.6,8 Many works compiling information regarding 
herbal remedies and medicines followed, of course, in the centuries proceeding such ancient 
civilizations. Over time, some cultures came to value approaches to medicine that excluded any 
superstitious nature. This is evidenced by the works of ancient Greek authors, such as Hippocrates, 
Aristotle and Dioscorides. The efforts of the ancient Greek physicians during this time period (460 
BC to around AD 78) gave rise to works of great importance, such as the Hippocratic corpus, and De 
Materia Medica.6 It should be noted that the use of medicinal herbs remained empirical, with little 
being known regarding the plant constituents causing the observed effects, and only some of the 
species in use being effective. 
Towards the end of the 15th century (AD), exploratory voyages began to open new trade routes, and 
it became possible for European nations to access herbs from the Americas. Coupled with the 
development of the printing press in the mid-15th century, this lead to the publication of ‘herbals’, 
documenting investigations of herbs, medicinal and otherwise.9 Herbals grew in popularity, leading 
to an increased focus on plants as medicines, and encouraging physicians to carry out and publish 
their own investigations.6 This assisted in shifting the medicinal approach somewhat towards the 
logical, and away from the magical and ethereal.  
Around the late 18th century, physicians finally began to carry out medical investigations that 
resembled the modern scientific approach.6 James Lind famously developed a method for the first 
clinical trial, when he ran experiments testing the efficacy of various scurvy treatments on sailors and 
hospitalized scurvy patients10 (though it has been proven that much earlier, others reached the 
conclusion that citrus fruits were a cure,11 the trial itself reflected a scientific approach10). Soon after, 
during the mid- to late-18th century, other physicians began to conduct their own scientific studies on 
plant medications. Examples of such include Anton von Störck - who carried out dosage 
investigations on species of plants that were generally considered poisonous at the time - and William 
Withering, known for his reports on foxglove (Digitalis purpurea L.).6 Such investigations as these 
indicate a shift towards a scientific approach, which eventually lead to investigations resulting in the 





6.1.2 A brief history of natural products chemistry 
As is outlined in the preceding section, crude plant remedies in many forms have been in use for 
thousands of years. However, as is well known, modern medicine is based almost entirely on the 
premise of utilising pure compounds and establishing their interactions within the human body. The 
use of pure bioactive organic compounds as drugs began when they were first isolated from plants.  
Though several naturally isolated organic acids were first discovered by Carl Wilhelm Scheele in the 
late 18th century,12 these substances did not exhibit high bioactivity by interaction with receptors in 
the human body, and thus (despite having many uses and health effects), are not of the same class of 
drugs as the compounds to follow.  
The discovery of highly active drug compounds began, quite famously, with the isolation of morphine 
1 from the opium poppy, Papaver somniferum, which was carried out by Friedrich Wilhelm 
Sertürner.6,13,14 Sertürner published his first report on this in 1805,13 and a year later, published a more 
detailed account of the isolation of this principal active of opium.6,12,15,16 He called the substance - 
which he determined to be alkaline in nature - ‘morphium’,6,17 after the Greek god of dreams. 
“Morphium” was the first known plant substance that was basic in nature. The importance of this fact 
was noted by Joseph Gay-Lussac, when he noticed a report published by Sertürner in 1817, in which 
attention was drawn to the ability of “morphium” to form salts when reacted with acids.6 Gay-Lussac 
was a highly respected French chemist, and the editor of the prestigious Annales de Chemie, in which 
he published Sertürner’s work, bringing attention to the existence of plant alkalis, and sparking further 
investigation of such species by chemists.6,16 Gay-Lussac suspected that more such compounds would 
be found, and suggested a convention in which their names end in the suffix ‘-ine’. It was in this way 
that the first isolated natural products drug was named ‘morphine’ 1 (Figure 6.1.1). To this day, 
morphine 1 (generally in a salt form) remains in common use as an analgesic for the treatment of 
moderate to severe pain.16–18 
 
Figure 6.1.1 - The chemical structure of morphine 1. 
At this point, it may be necessary – as a disclaimer – to note that narcotine 2 (Figure 6.1.2) (or 




alkali. It was first isolated by Charles Louis Derosne in 1803.6,12 Interestingly, it seems he noticed its 
basic nature, but ascribed it to the use of potash in the procedure during which it was obtained.6 The 
reason this has been omitted is due to the lack of further investigation following its isolation, and the 
fact that it was only named and classified well after morphine 1 had set the stage for alkaloid 
discovery.6,12 
 
Figure 6.1.2 - The chemical structure of narcotine 2. 
Opium was of high interest for the isolation of active alkaloids, and several others were later 
discovered in this species. Thebaine 3 (Figure 6.1.3) was isolated in 1832 by Thibouméry, the 
manager of a factory built by Pelletier (see discussion of quinine 12 ahead) for alkaloid production.6 
Thebaine 3 did not exhibit great potential as a pharmaceutical agent, but has since proven very useful 
as a subject for synthetic studies on morphine-related opium alkaloids.6,21 Also in 1832, Pierre-Jean 
Robiquet discovered a new alkaloid while exploring an alternative morphine 1 extraction process.21 
This was called codeine 4 (Figure 6.1.3) and it exhibited pharmacological action similar to – but less 
pronounced than – that of morphine 1. Codeine 4 is still used as treatment for mild to moderate pain 
today. In 1848, George Merck isolated another alkaloid called papaverine 5 (Figure 6.1.3) from the 
mother liquor remaining after morphine 1 extraction in his father’s factory.21  
 
Figure 6.1.3 - The chemical structures of thebaine 3, codeine 4 and papaverine 5. 
The discovery of the first of the plant alkalis (later termed the ‘alkaloids’) was the frontrunner in a 
series of similar alkaloid isolations.6,16 Nicotine 6 (Figure 6.1.4) was isolated in impure form in 1809, 




1817,6,12,16 though the pure alkaloid was only isolated in 1887.22 This alkaloid was used as a treatment 
for amoebic dysentery.6,16 In 1819, impure colchicine 8 (Figure 6.1.4) was isolated for the first time, 
by the French chemists Pelletier and Caventou,16,23 and was of interest for its application as a gout 
treatment. Currently it is used for the treatment of a variety of diseases and conditions.23 Again, this 
alkaloid was only isolated in its pure form much later in, 1883.23 Pelletier and Caventou isolated 
several other alkaloids in 1819, including strychnine 9 and brucine 10 (Figure 6.1.5).12 Delphinine 11 
(Figure 6.1.5) was also isolated that year, by J.-L. Lassaigne and H. Feneulle.12 
 
Figure 6.1.4 – The chemical structures of nicotine 6, emetine 7 and colchicine 8. 
 
Figure 6.1.5 – The chemical structures of strychnine 9, brucine 10 and delphinine 11. 
Quinine 12 (Figure 6.1.6), also isolated by Pelletier and Caventou, in 1820,24 was the next significant 
alkaloid discovery, and proved to be a highly impactful one. It was isolated from the bark of Cinchona 
cordifolia, while the researchers were investigating the material based on work done by Bernardino 
Gomes, who isolated impure cinchonine from the bark around 1812.6,12 During their investigation, 
Pelletier and Caventou isolated both cinchonine and quinine 12. Quinine 12 was shown to be effective 
in the treatment of malaria, caused by the parasite Plasmodium falciparum. It remained the primary 
antimalarial drug for many years, and its bulk production in a factory in 1826 by Pelletier  could be 
considered the birth of the pharmaceutical production industry.6,16 Other alkaloids isolated in 1820 





Figure 6.1.6 - The chemical structure of quinine 12. 
Caffeine 13 (Figure 6.1.7) was isolated from mocha beans by Ferdinand Friedlieb Runge in 1821.6 
The beans of Coffea arabica have continued to be used in brewing the popular stimulating beverage 
that is coffee to this day. Before the introduction of synthetic diuretics, caffeine 13 and other xanthine 
alkaloids were often prescribed as diurectics. Other xanthine alkaloids include theobromine 14, 
isolated from Theobroma cacao seeds in 1878 and theophylline 15, isolated from Camellia sinensis 
in 1888 (Figure 6.1.7).6  
 
Figure 6.1.7 – The chemical structures of caffeine 13, theobromine 14, and theophylline 15. 
Atropine 16 (Figure 6.1.8) is a tropane alkaloid, first isolated as a crude compound in 1822 by 
Rudolph Brandes. It was isolated in pure form in 1833.6 Atropine 16 is an example of an artefact, 
which is a compound formed during the extraction or isolation processes, and is not present as such 
in the plant.6,25 Atropine 16 is a racemate of hyoscyamine 17 (Figure 6.1.8), the source alkaloid, 
present as one stereoisomer, which forms a racemic mixture when in solution.6,25 Artefacts produced 
during the isolation of alkaloids is something that must always be considered as a possibility by a 





Figure 6.1.8 - Chemical structures of atropine 16 and hyoscyamine 17. 
An alkaloid which is well-known in modern society, though unfortunately not as a prescribed 
medicine, is cocaine 18 (Figure 6.1.9). Cocaine 18 is a stimulant, originating from the leaves of the 
coca plant, Erythroxylum coca. The leaves of the coca plant have been in use by indigenous 
inhabitants for centuries, with the first documented report of their use being published in 1565.6 The 
popularity of the use of coca leaves sparked an intensive investigation of the plant by organic 
chemists, resulting in the isolation of the active alkaloid, cocaine 18, in 1860  by Albert Niemann.6,26 
Interestingly, cocaine 18 was investigated by Sigmund Freud for its stimulating properties. Carl 
Koller, Freud’s assistant at the time, noticed the ability of cocaine 18 to cause numbness when applied 
to an area, an application which ended up offering significant contribution in the field of ophthalmic 
surgery.6,27 This discovery is considered the first instance of a local anaesthetic.27 
 
Figure 6.1.9 - The chemical structure of cocaine 18. 
The nineteenth century was thus the opening chapter for an ever-expanding archive of alkaloidal 
discoveries. Other alkaloids isolated in the  19th and 20th centuries include: physostigmine, obtained 
in 1864; pilocarpine in 1874  (a rare example of a natural product that has not had analogues made, 
as it was sufficiently active and was acceptable for its specific application); ephedrine in 1885; 
tubocurarine in 1935; reserpine in 1951; vinblastine in 1958; and vincristine in 1961 (this and 
vinblastine being of the vinca alkaloids, and of use in cancer therapy).6 
As can be noted, up until this point, only alkaloidal isolations have been mentioned in this section. 
Though the use of alkaloids is stressed, due to the focus of this project, it must be noted that there 




As briefly mentioned above, there were several organic acids isolated by Carl Wilhelm Scheele, 
between 1770 and 1790.12 These acids included: tartaric acid in 1770, benzoic acid in 1775, citric 
acid in 1784, oxalic acid in 1784, malic acid in 1785, glucuronic acid in 1785, and gallic acid in 
1786.12 
Inulin (though not a pure compound) was found in 1804 by Valentin Rose Jr., from the roots of 
elecampane (Inula helenium).12 Inulin is a term applied to all β(1→2) fructans, a group of 
polysaccharides. Inulin has been shown to act as a prebiotic, promoting the growth of beneficial 
microbes in the gut, assisting in the formation of a healthy gut flora.28 
Salicin was isolated in 1829 by Leroux, from meadowsweet, Filipendula ulmaria. Salicin was first 
used as an alternative to quinine 12, as it assisted in abating the fevers that invariably accompany 
malaria. It was later found that salicin could be transformed into salicylic acid, and that this process 
occurred in the human body when salicin was ingested.6,29 Salicylic acid was synthesised in 1860, 
and became a cheaper alternative to salicin, the use of which declined for this reason.6,29 The common 
drug known as aspirin is derived from salicylic acid, being its acetic acid ester.29 Methyl salicylate 
(the methyl ester of salicylic acid) was isolated by William Proctor in 1843, from wintergreen oil.6 
Another noteworthy isolation was that of podophyllotoxin in 1880 by Podwyssotski,30 from the 
rhizome of Podophyllum peltatum. Podophyllotoxin is very toxic, and has pronounced 
gastrointestinal side effects,6 but exhibits potent cytotoxic biological activity.6,31,32 The generation of 
analogues of podophyllotoxin has yielded several useful anticancer agents, such as etoposide and 
teniposide.31,32 Derivatisation of podophyllotoxin in search of anticancer agents remains a subject of 
interest to this day.33 
A screening programme established by the US National Cancer Institute resulted in the isolation of 
another useful anticancer drug in 1966,6 called paclitaxel (taxol). Paclitaxel is active against a broad 
range of cancer types, and has approved applications in the treatment of ovarian and breast cancers.6,34 
The information above provides only a very broad overview of just a few examples of some historical 
plant-based natural products and their medicinal contributions. The true contribution of natural 
products to modern medicine is immense, and in fact extends beyond the plant kingdom, with many 
notable contributions from animals, bacteria and fungi. The focus of this project is plant-oriented, and 
so the importance of plant-based medicinal chemistry is highlighted. As has hopefully been shown, 
even disregarding the contributions from other natural products sources, the potential of plants for 





6.1.3 What plants offer medicinal chemistry 
As the previous section demonstrates, there are numerous compounds that have been isolated from 
plants which have proven to be medicinally valuable. A concept that has added immense value to the 
field of medicinal chemistry is that of the generation of analogues of new molecular entities. 
Previously, morphine 1 was discussed as the first biologically active compound to be isolated from a 
plant. Perhaps as a result of this early development, morphine 1 was also the subject of studies 
resulting in the preparation of the first natural product analogues, by Henry How in 1853, who 
generated quaternary ammonium salts of morphine 1 by heating it with alkyl iodides.6 
Such analogues were only tested pharmacologically when, 15 years later, Alexander Crum Brown 
sent the quaternary ammonium salts of several alkaloids to Thomas Fraser for testing. Despite the 
diverse actions of the original alkaloids, the quaternary ammonium salts all exhibited paralytic 
activity.6 This suggested that the quaternary ammonium function conferred this particular property. 
Such was the result of the first known study correlating a structural feature to a specific activity.6  
When the first structural modifications resulted in compounds that exhibited notably different 
pharmacological properties, the concept of structure-activity relationships (SARs) was encountered. 
The idea that the properties of a drug could be improved, in a directed fashion, by making changes to 
one or more of its functional groups has proven to be of immense value in the field of drug 
development. It thus transpired that natural products compounds were of use, not only as immediately 
marketable drugs, but as drug leads that could be structurally altered for improved activity. It is 
therefore important to include natural products analogues when discussing the contributions of natural 
compounds to modern treatment options.  
Despite the fact that plants and other natural sources were the origin of the first pharmacologically 
active compounds, focus later shifted to synthetic approaches for drug discovery, due to the advent 
of high-throughput screening strategies.1,6,35 However, it seems as though synthetic approaches have 
not provided as many viable drugs as hoped for in recent years, resulting in a renewed interest in 
natural products for drug lead discovery.1,7,35–38 There seems to be an increasing interest in herbal 
medicines amongst the general public as well, which could be a contributing factor to the acceleration 
of natural products research.39 Regardless, it is apparent that there is value to be found in biological 
compounds, and that research in this area is well-justified.  
The contribution of natural products to the field of drug discovery is significantly dependent upon 
what one defines as a natural products contribution. There are several sources outlining recent 
information on this topic, with definition-dependent statistics ranging from about one third to around 




According to a paper by Thomford et al. published in 2018,36 of all drugs approved by the Food and 
Drug Administration (FDA) and/or the European Medical Agency (EMA),  about a quarter have been 
plant-based. About a third of the drugs approved over the last two decades were said to have been 
natural products-related, with added contributions from bacteria, fungi, animals and other natural 
sources.  
Thomford et al. refer to a paper published in 2016 by Patridge et al.41 when stating that a quarter of 
the approved drugs have been plant-based. Considering the data presented by Patridge et al., it seems 
a misunderstanding occurred. Patridge et al. report that over a third (38%) of all approved drugs are 
natural products related, and that of this percentage, approximately one quarter are based on plant 
compounds and their derivatives. Interestingly, this paper reports that 44% of approved natural 
products related drugs were from mammalian sources. 
Patridge et al.41 considered fully synthetic compounds related to their original natural counterparts as 
derivatives of natural products. The reason this makes a notable difference may be because most 
(around 80%) of the approved mammalian related drugs are fully synthetic (yet natural product-
inspired).41 Thus, if these are considered as natural products contributions, the statistics concerning 
mammalian input increase drastically. The information regarding non-mammalian natural products 
showed a higher percentage of unmodified compounds and their derivatives versus fully synthetic 
analogues.41 In this data, plants dominated the non-mammalian contributors, though bacteria are 
gaining increasing interest in more recent years.41 Also highlighting plant contributions, Alan Harvey 
reported in 2008 that there were over 200 natural products undergoing preclinical and clinical trials, 
almost half of which were plant-related.7  
Anticancer agents are a group of medicines with a particularly high contribution from natural 
products, with approximately 74% of anticancer drugs in 2006 being natural products or natural 
products derived.42 A more recent report, published in 2019 by Jin and Yao,43 states that over 75% of 
small molecule anticancer drugs are natural products or are directly related to them. This indicates 
that the trend in natural products contributions to cancer treatments still prevails, and has not 
diminished to date.  
The purpose of this section is to outline the significance of plant contributions to the medical world 
today. The topic of natural products contributions can become fairly complicated when considering 
the variety of definitions, and so it may not be within efficiency’s best interests to go into too much 
detail. The above information should be sufficient to convince the reader that natural products play a 
significant role in the drug discovery field, and that plant products are an important resource in natural 




Despite the inherent value of plant extracts as a resource for the discovery of new medicinal 
compounds, only an estimated 10-15% of the higher plant species on earth has been investigated for 
medicinal potential44. Thus, there remains a largely untapped resource in plant biodiversity.  
South Africa is a region of notable plant biodiversity, being home to over 23000 plant species,45 
which is over 8% of the world’s plant species, while covering less than 1% of earth’s land surface.45,46 
The “fynbos” eco-region of the Cape Peninsula alone holds over 9000 plant species – a total of around 
3.4% of the world’s plant species.45 This Cape Floral Kingdom represents more than 40% of the 
subcontinent’s flora, in only 4% of its area. Of the plants found in this area, 6192 species are found 
nowhere else – a remarkable level of endemism.45 It is therefore clear that southern African plants 
hold an immense and untapped value in terms of species to be investigated for medicinal 
advancement. Investigations focusing on exploring this resource are therefore of importance. Not 
only are such investigations of interest for adding value to the medicinal world, but proving the 
existence of such value in South African biodiversity may provide additional motivation for the 
conservation of these biomes. Such reasoning was a factor backing the decision to focus on a southern 
African plant as the subject of investigation for this project.  
One possible outcome of this project was the isolation of active principles that were novel, in an 
attempt to provide new drug leads for further development. To increase the chances of success in this 
regard, choosing plant species that had not previously been thoroughly investigated was an obvious 
advantage. Additionally, plant species from families known to be rich in active compounds were of 
high interest. With such reasoning in mind, two species were selected, namely Crinum paludosum, 
and Crinum variabile. Members of the Crinum genus have a history of use in traditional medicine47, 
also adding to the likelihood of active isolations. These species are of the Amaryllidaceae family, 
which has provided a plethora of novel alkaloid structures.48–51  
The Amaryllidaceae alkaloids are a structurally diverse group, and have a broad range of 
pharmacological actions, with several possible areas of application.49,51    
6.2 The Amaryllidaceae alkaloids 
6.2.1 An introduction to the Amaryllidaceae 
The Amaryllidaceae is a family of monocotyledonous plants containing 75 genera and around 1600 
species.52 Southern Africa is a region of pronounced diversity with regards to the Amaryllidaceae, 
containing 18 genera and around 250 species, all within the subfamily Amaryllidoideae53 (the old 
Amaryllidaceae54). This diversity is bested only by the Neotropics from Mexico to Chile, which 




containing 8 genera within the family. Of the 18 genera present in southern Africa, all but three 
(Crinum, Pancratium and Scadoxus) are endemic to Africa, and of those, all but four are endemic to 
southern Africa.53 The 11 genera endemic to southern Africa contain over 200 endemic species, with 
local centres of diversity in the southwest Western Cape, the Eastern Cape and the escarpment 
between Kwa-Zulu Natal and Mpumalanga.53  
In Africa, four tribes within the subfamily Amaryllidoideae are represented. Of these four tribes 
(Amaryllideae, Cyrantheae, Haemantheae, and Pancratieae), Amaryllideae contains the most genera, 
this being 10 – more than all three other tribes combined. Within the Amaryllideae tribe, Crinum is 
the largest genus, containing approximately 65 species in southern Africa,53 and around 103 species 
in total.48 Crinum has its origin and centre of diversity in southern Africa, though it has species present 
in several other regions, including Madagascar, Asia, Australia and America. The genus was first 
established in 1753, then containing only 4 species, three of which are still recognized as valid today. 
All species within the genus are summer-growing, with the exception of C. variabile, which is winter 
growing.53  
There are many examples of Amaryllidaceae members, such as species of the Crinum genus (and 
several others), which have a history of use in traditional medicine. There are examples of some 
species being used for the treatment of ailments such as (among many more47) joint pain, backache, 
rheumatism, earache, colds, urinary tract infection, and even kidney and bladder disease.47,53 The 
plant material of several southern African Crinum species, including C. campanulatum, C. 
gramnicola, C. moorei, and C. variabile (as well as many species of other Amaryllidaceae genera) 
have shown positive results for acetylcholinesterase (AChE) inhibition, and have potential for 
Alzheimer’s disease treatment.53,55–58 
It has been shown that this activity (and many other pharmacological activities) can be attributed to 
the alkaloids present in these species, and that such alkaloids are present in species belonging to 
genera across the whole family of the Amaryllidaceae.50,59,60 It seems, in fact, that most genera in the 
family have been validated to produce Amaryllidaceae alkaloids.54  
The alkaloids present in members of the Amaryllidaceae, referred to as the “Amaryllidaceae 
alkaloids”, are structurally diverse, and numerous. According to Jin and Xu (2013),54 up to 500 
alkaloids had been isolated up until 2013. With more being isolated every year, this number has now 
increased to over 600, as reported by a review published by Jin and Yao in 2019.43 The book chapter 
published by Jin and Xu in 2013 is an extensive review of the Amaryllidaceae alkaloids, with 169 
references, and outlines the structures of well over 200 known Amaryllidaceae alkaloids.54 Also 




alkaloid types, and the biological activities of a number of these alkaloids. The review paper published 
in 2019 by Jin and Yao43 in Natural Product Reports is the most recent in a series of review articles 
entitled “Amaryllidaceae and Sceletium Alkaloids”. This article comprises a comprehensive analysis 
of alkaloids isolated from the Amaryllidaceae family, and the closely related alkaloids from the 
Sceletium genus, from mid-2015 until mid-2017. This review series frequently covers the topic, and 
contains a compilation of information that is challenged by few, if any, other sources.  
The first known Amaryllidaceae alkaloid, lycorine 19 (Figure 6.2.1), was isolated in 1877, from the 
species Narcissus pseudonarcissus. Lycorine 19 has since been shown to exhibit a range of biological 
activities, including: apoptosis-inducing effect, antitumor, antiviral, anti-inflammatory, antifungal, 
antimicrobial, antimalarial, antiretroviral and AChE inhibitory activities.54 Lycorine 19 has drawn 
much attention as a possible natural lead for anticancer drug design, showing activity against several 
cancer types, including drug-resistant variants, at low concentration and with high specificity.61 
As has been established, since the discovery of lycorine 19, the number of known Amaryllidaceae 
alkaloids has increased significantly, revealing diverse structures and pharmacological activities. 
Well known amongst these is galanthamine 20 (Figure 6.2.2) (also known by the drug name 
galantamine, Reminyl®), a potent AChE inhibitor that was approved as a prescription drug for the 
treatment of Alzheimer’s disease in 2001.43,54,62 Galanthamine 20 is produced on an industrial scale 
by extraction and isolation from daffodils, though total synthesis is also possible as a means of 
production.43 The value of the galanthamine 20 industry as reported in 2013 by Nair et al.62 was 
approximately 150 million US dollars per year. 
Also according to Nair et al. (2013),62  an anticancer drug target related to the Amaryllidaceae alkaloid 
pancratistatin was undergoing advanced clinical evaluation, and was expected to be commercially 
available by 2023. This is indicative of the value and potential present in the development of analogue 
libraries of Amaryllidaceae alkaloids for the discovery of new drugs.  
6.2.2 Classification of Amaryllidaceae alkaloids 
Despite the notable structural diversity of the Amaryllidaceae alkaloids, they share biosynthetic roots 
and are considered to be biogenetically related.54 They are biosynthetically derived from the precursor 
norbelladine,54,61,63 which is an alkaloid present in some Amaryllidaceae species. The nature of their 
biogenetic relation is such that their production in a plant is considered a fairly reliable indicator of 
that plant’s classification in the family (since these alkaloids are almost entirely exclusively produced 
by plants in this family). Thus, should a genus or species produce only unrelated alkaloids, 




Initially, the Amaryllidaceae alkaloids were classified, based on skeletal structure, into 9 groups.54 
However, following the discovery of alkaloids with skeletons that challenged classification based on 
this convention, a new grouping system was suggested shortly prior to 2013.54 The new convention 
classifies Amaryllidaceae alkaloids based on skeletal ring systems into 12 possible groups, as follows: 
[1] norbelladine-type, [2] lycorine-type, [3] homolycorine-type, [4] crinine-  and haemanthamine- 
types, [5] tazettine-type, [6] montanine-type, [7] plicamine-type, [8] graciline-type, [9] galanthindole-
type, [10] galanthamine-type, [11] phenanthridone- and phenanthridine-types, and [12] other minor 
species populations.54 This convention is the currently accepted rubric for Amaryllidaceae alkaloid 
classification.43  
Table 6.1 – Examples of skeletal structures for each Amaryllidaceae alkaloid type. Note that each type may have additional skeleton 
structures which are related to those shown. R1-R6 = various groups. 










6.2.3 Some Crinum alkaloids and their applications 
As mentioned in Section 3.2.2, members of the Crinum genus have a long history of use in traditional 
medicine for the treatment of numerous conditions and ailments. Extracts and isolates of Crinum 
species have been scientifically shown to exhibit a range of pharmacological properties.47 Two 
important alkaloids commonly isolated from members of the Crinum genus, which have already been 
briefly discussed, are lycorine 19 and galanthamine 20,64 with lycorine 19 exhibiting promising 
potential as an anticancer drug lead, and galanthamine 20 already having found its place as a treatment 
for Alzheimer’s disease.54 
Lycorine 19 has been the subject of several studies reporting positive results regarding the anti-
tumour activity of it and its derivatives.61,63 Lycorine 19 itself has been shown to possess activity 
against many cancer types.61 Zhang et al. (2019)65 studied the activity of lycorine 19 against 
metastatic melanoma, a cancer type responsible for 60% of skin cancer deaths. They reported that the 
alkaloid significantly suppressed melanoma cell migration and invasion in vitro, and when tested on 
tumour-bearing mice, decreased the metastasis of melanoma cells to the lung tissue. This resulted in 
a significant increase in survival time of the treated mice, without obvious toxicity. Another study by 
Sun et al. (2018)66 tested lycorine 19 against non-small cell lung carcinoma, reporting that treatment 
resulted in significant suppression of the growth and metastasis of the lung tumour.  






Reports of the activity of lycorine 19 against other cancer types are extensive in the literature. The 
topic is outlined by Roy et al. (2018),61 which reviews the alkaloid and its mechanisms of action for 
anticancer activities. Examples of cancer types against which lycorine 19 is active include leukaemia, 
multiple myeloma, prostate cancer, human breast cancer, human bladder cancer, ovarian cancer, large 
cell lung cancer, colon carcinoma and human heptatocellular carcinoma.61 Against all of these, 
lycorine 19 exhibited IC50 values below 40 µM.  
 
Figure 6.2.1 - The chemical structure of lycorine 19. 
Derivatives of lycorine 19 have also been shown to exhibit activity against a range of cancer types, 
some examples of which are outlined in an article by Lamoral-Theys et al. (2010).63 This paper 
reviews the testing of 25 lycorine 19 derivatives on various cancer cell lines, reporting that 20 of these 
proved active against at least on cell line. Additionally, it is stated that there were approximately 300 
molecules sharing lycorine’s core ring structure in 2010 (this number has likely increased). That only 
26 of these (including lycorine 19) had been tested is testament to the work that has yet to be done on 
this topic.  
Galanthamine 20 is an additional example of an Amaryllidaceae alkaloid of especial importance, and 
is, to the best of our knowledge, the only Amaryllidaceae alkaloid to be marketed as an approved 
drug in the developed world.43,54 As briefly discussed previously, galanthamine 20 is approved for 
use in the treatment of Alzheimer’s disease (approved by the FDA). Alzheimer’s disease is the most 
common form of dementia among elderly individuals67 and is also the most prevalent chronic 
neurodegenerative disease, affecting around 5.7 million people in the US alone.68 Worldwide, it is 
estimated that there are 50 million people suffering from dementia, 30-35 million of which have 
Alzheimer’s.68  
One of the effects of the disease is the loss of cortical acetylcholine receptors, which are important 
for the passage of signals through synapses in the brain. Acetylcholine is a neurotransmitter which 
binds to these receptors as a means of transmitting signals between synapses. Thus the loss of these 
receptors weakens impulses passing between synapses, slowing cognitive function. Galanthamine 20 




catabolism of acetylcholine in the synaptic cleft. Inhibition of the enzyme that breaks down 
acetylcholine allows for an increase in the number of receptors being activated by the 
neurotransmitter, thus allowing for better inter-synaptic signalling despite decreased receptor 
density.67  
Galanthamine 20 has also been used in anaesthesia to reverse neuromuscular paralysis caused by 
some muscle relaxants.67 As mentioned previously, the alkaloid is produced industrially by extraction 
and isolation from daffodils, but can be generated synthetically.54 Much of the recent literature 
concerning galanthamine 20 is dedicated towards options for its synthesis. 
 
Figure 6.2.2 - The chemical structure of galanthamine 20. 
Lycorine 19 and galanthamine 20 are just two examples of alkaloids present in Crinum species that 
exhibit promising bioactivities. There are, of course, numerous other alkaloids present in members of 
the genus, with Refaat et al. (2012-2013)48,69,70 producing a review series which presents around 180 
different alkaloids reported from Crinum species. The fifth part in this review focuses on the 
biological profile of the genus and reports the pharmacological activities of extracts from some of 
these plants, and of some of the alkaloids found within them. Amongst the activities reported are: 
analgesic and anti-inflammatory effects, acetylcholinesterase inhibition, serotonin reuptake 
inhibition, hypotensive and hypertensive activities, muscle relaxant and reversal thereof, antiallergic 
and anti-anaphylactic activities, immunomodulatory properties, cytotoxic and anticancer, 
antimicrobial, antiparasitic and insecticidal activities.71  
With such a diverse range of possible applications, and such a complex alkaloidal profile, 
investigations into the detection, isolation and characterisation of alkaloids from such plants has 
drawn much attention in the scientific community. Methods that can be applied to such investigations 
are thus of great interest.  
6.3 A brief overview of some methods of natural product analysis 
With the immense diversity presented by nature comes a diverse and multidisciplinary set of skills 




incorporates the use of many methods, often resulting in a number of possible approaches to a task. 
With the advancement of technology comes the development of new instrumentation and faster, more 
effective, techniques for the detection, isolation and characterisation of natural products compounds. 
It must, however, be acknowledged that the circumstances of the researcher play a determining role 
in the approaches taken during an investigation. Aspects such as available instrumentation, time 
restrictions, financial limitations, availability of trained collaborators and many other such resource 
and personnel limitations must be considered guiding forces in research projects.  
When access to analytical instruments is limited by such restrictions, sometimes the most effective 
approach is the application of simple techniques such as solvent extraction, thin layer chromatography 
(TLC) and gravity column chromatography. The use of such techniques still holds a place in (even 
the most established) laboratories worldwide, and their efficacy cannot be challenged.  
With this in mind, recent years have seen the development of some fascinating and effective 
techniques for natural products investigations. The use of high-performance liquid chromatography 
(HPLC) has established itself, and has proven to be of great use, with hyphenation to a number of 
detection methods further increasing its power. Ultraviolet/visible (UV/Vis) and infrared (IR) 
spectroscopies, and mass spectrometry (MS) are common examples of such detection methods, 
though even powerful structural elucidation tools such as nuclear magnetic resonance (NMR) 
spectroscopy can be hyphenated to such systems.72  
When searching for natural compounds with a specific pharmacological action, bioassays can be 
employed as useful tests for the detection of compounds exhibiting the required action. In the book 
edited by Colegate and Molyneux (2008),72 such a bioassay is defined as “…any in vitro or in vivo 
system used to detect the biological activity of an extract or a pure substance…”. Bioassays are 
numerous and varied, ranging from general to very specific. A plethora of systems are used as tests, 
ranging from cell cultures to developed lab animals, and thus a range of properties and applications 
are exemplified in the field. Bioassay-guided fractionation is the process in which bioassays are used 
to determine the presence of bioactive substances in fractions throughout a series of separation steps, 
leading towards the isolation of a pure bioactive compound. Bioassays can, unfortunately, be time-
consuming, and studies focused on increasing their speed continue.72 
Important steps for the characterisation of natural compounds are, of course, separation and isolation. 
The first step in such processes is generally extraction of the original biological material. Sometimes 
this is done with sequentially low- to high-polarity solvents, but generally, polar alcoholic solvents 
are useful as they rupture cell membranes, and can thus extract more endocellular metabolites.72 Thus, 




Selective extraction processes can then be applied to the crude total extract achieved in this way, 
some examples being trituration with less polar solvents and acid/base extraction. 
Isolation of a compound from a crude extract, or from fractions thereof, can be a demanding task, 
often requiring several separation steps and multiple chromatographic methods. There are many 
available methods of chromatographic separation, some of which will be outlined below.  
Liquid-liquid chromatography involves the use of two immiscible liquid phases, and the mechanism 
relies on differing partition coefficients of the compounds in each of the solvents. Countercurrent 
chromatography (CCC) is an example of this, though HPLC and other solid support methods were 
preferred when it was developed, so it was largely overlooked.72 Modern CCC, however, is much 
improved compared to the technique at its conception, and current advantages include: total recovery 
of loaded sample due to no irreversible adsorption, little risk of sample degradation, low solvent 
consumption, variability of both phases, and no need for expensive replaceable columns.72 
A chromatographic type containing several popular techniques is that of planar chromatography. This 
covers chromatographic techniques in which the stationary phase is in a flat bed arrangement. 
Included in this are the widespread and indispensable TLC technique, preparative TLC (PTLC) – 
used for separation of larger sample quantities – and centrifugal TLC (CTLC). CTLC utilises a 
circular preparative plate, which is rotated while inclined, allowing for concentric circular bands to 
be collected as they reach the plate’s edge. The sample is loaded at the centre of the plate, and can be 
eluted using a solvent gradient. Additional advantages include the ability to reuse plates, possible 
coupling of detectors, and the ability to carry out inert separations.72 
Not to be forgotten in the separation of organic compounds is the concept of column chromatography. 
With a broad range of possible stationary phases, there are many techniques covered by the term. Gel 
filtration (also known as size exclusion chromatography) uses a gel stationary phase to separate 
compounds by molecular size. Conventional preparative column chromatography is gravity-driven 
with a silica, derivatised silica and ion exchange as stationary phase examples, and is used extensively 
in chemistry laboratories. Flash chromatography is similar, though solvent is forced through faster 
with pressure at the top of the column.72  
Modern hyphenation methods (mentioned above), using separation systems such as HPLC and gas 
chromatography (GC) provide unchallenged resolution, and are imperative for dereplication 
processes. Dereplication is the process of identifying known compounds in extracts before searching 
for novel bioactive compounds, such that the search is more likely to provide previously 
uncharacterised drug leads. Dereplication of extracts containing known compounds can be carried 




noted that the instrumentation for such systems can be exceedingly expensive, so numerous 
laboratories do not have access to many of these options.  
As is well-known, and generally undisputed, nuclear magnetic resonance (NMR) spectroscopy is the 
most powerful structural elucidation tool currently available at most academic institutions, and the 
technique is improving as better instrumentation and experimental control are achieved. Both 1D- 
and 2D-NMR spectroscopy techniques are indispensable for natural products research, providing 
structural information that can rarely be matched. Some research groups are even using it as a first 
step in natural products investigations, obtaining the NMR spectra of a total extract to provide some 
information on the constituents, and to indicate any changes occurring during the fractionation 
process. Another interesting application is the development of quantitative NMR (qNMR) 
spectroscopy, which has the advantage of being non-destructive, which is particularly useful for 
natural products present in trace amounts.72 
A hyphenation method of particular note and promise is that of HPLC-NMR. With NMR 
spectroscopy being such a powerful structural elucidation tool, and HPLC being a versatile method 
of separation with relatively simple sample preparation, the combination of the two could prove to be 
extremely valuable for natural products research. Current limitations of direct hyphenation include 
large solvent peaks, under which other peaks are hidden, chemical shift differences, and lack of 
sensitivity.72 Such limitations reduce the possible application of the technique, though solutions to 
these could result in a particularly powerful analytical tool. Needless to say, the method is also a 
costly one. 
The methods mentioned above are only a few examples, and many more exist, with varying 
specificity of application. The nature of the research being carried out thus dictates the methods that 
will be useful, and decisions must be made taking the strengths and weaknesses of such methods into 




7 Aims and objectives 
As illustrated in the above sections, this project was focused on the investigation of the alkaloidal 
profiles of Crinum variabile and Crinum paludosum. These species were chosen because their 
alkaloid profiles had not previously been studied in depth, and because they belong to a family of 
plants with a history of use in traditional medicine. The family (Amaryllidaceae) also boasts a unique 
and promising record of alkaloid isolations. An additional advantage was the bulbous nature of the 
species, as bulbs act as storage organs for secondary metabolites and other plant products, and thus 
contain higher alkaloid concentrations.47  
The aim of this project was to isolate and identify the major alkaloidal constituents of Crinum 
variabile and Crinum paludosum. These investigations add value to the field of natural products 
chemistry by identifying the major alkaloids present in the species, a task that has not previously been 
undertaken. This provides information to future researchers and contributes towards the body of 
knowledge on medicinal compounds available in the plant species in southern Africa. In the event of 
the isolation of a novel compound in sufficient quantities, a small library of semi-synthetic analogues 
could then be generated for a brief structure-activity relationship (SAR) study.  
Also within the objectives of this project is a very brief synthetic study on two compounds, 
higginsianin A and higginsianin B. These two compounds are natural products isolated from the 
fungus Colletotrichum higginsianum by Cimmino et al.73 Small quantities of these compounds were 
obtained from the original research group, with the intention of running small-scale test reactions for 







8 Crinum variabile  
8.1 Introduction 
Crinum variabile is a winter-growing species, so named in reference to the variable colours of its 
flowers, which change from white to a deep pink as they age. The species is endemic to the north-
western, western and southern areas of the Northern Cape of South Africa and grows near winter-
flowing rivers in deep sand. It was originally classified as 
Amaryllis variabilis in 1804, with the first botanical 
illustration being drawn of a specimen obtained from the 
Cape of Good Hope. In 1873, it was transferred to the 
Crinum genus, but wild specimens were only rediscovered 
less than 60 years ago, in 1961. The species is easy to 
cultivate and micropropagation protocols have been 
established. However, flowering can be somewhat more 
difficult to achieve.53 
Crinum variabile has been the subject of some limited 
phytochemical investigations, having been mentioned in a 
paper by Tanahashi et al. (1990), entitled 
“Radioimmunoassay for the Quantitative Determination 
of Galanthamine 20”.74 In this paper, C. variabile was one 
of the species tested for galanthamine 20 content. The 
data presented shows that galanthamine 20 was found in 
small amounts, that being 0.006% of the dry weight of the plant material used.74  
Another paper mentioning the species was published in 2004 by Jäger et al., and was entitled 
“Acetylcholinesterase inhibition of Crinum sp.”.75 This paper did not focus on the isolation of active 
compounds from the species investigated, but rather tested the acetylcholinesterase inhibitory 
activities of extracts from the plants. Interestingly, the leaves of C. variabile exhibited the greatest 
activity in leaf extracts of the species tested. However, the C. variabile bulb and root extracts, while 
displaying significant activity, were not as active as those from some of the other species, with C. 
macowanii bulbs, and C. macowanii and C. moorei roots, exhibiting the greater activities.75 
To the best of our knowledge, there have been no in-depth investigations regarding the alkaloidal 
constituents of C. variabile. Thus, this investigation provides new information on the species and 
adds value to the field.  
Figure 8.1.1 – A botanical illustration of Crinum 
variabile, drawn by Barbara Jeppe, taken from “The 
Amaryllidaceae of Southern Africa” by Graham 




8.2 Processing, results and discussion 
Please note that there is a tree diagram present in Appendix A (Fig. A.1.1) which represents the 
processing of the plant material. It is recommended that this be referred to for context when reviewing 
the processes described below.  
8.2.1 Preparation and extraction 
The plant material was acquired as bulbs, purchased from a local nursery. This means of acquisition 
is preferable to removing natural specimens from their habitat, as it avoids depletion of wild 
populations. Two examples of live bulbs are thriving in the Botanical Gardens at the University of 
Stellenbosch (33°56'09.3"S 18°51'56.9"E) as reference material. A living specimen will be 
maintained in the Botanical Gardens, and in the case of its demise, this will be converted into a dried 
voucher specimen. 
The bulbs were cut into slices, and air dried until constant mass was obtained (7 days at 25 °C). The 
dried bulb material was placed in a sealed bag and stored in a freezer (approximately -18 °C) until 
further processing. To prepare for extraction, the dried bulb material was frozen under liquid nitrogen 
in a large mortar and pestle and crushed to as fine a powder as possible. This method proved very 
useful, as the material was otherwise fibrous and difficult to crush without first making it brittle. Of 
course, the goal of this treatment was to increase the surface area of the material to maximise 
efficiency of extraction. All of the available dry bulb material (139 g) was prepared in this way.  
The total mass of crushed, dry bulb was then covered with enough methanol to fully submerge it and 
allow for free movement during stirring, and the mixture was agitated with a mechanical stirrer for 2 
hours. The plant material was then strained, and the methanol collected. The plant material was 
extracted in this way with four such portions of methanol, each extraction being left and stirred for 2 
hours, except the fourth, which was left for 2 hours 40 minutes. All four portions of methanol extract 
were added together, and the solvent removed under reduced pressure. After drying for 3.5 hours 
under high vacuum, a total crude extract mass of 17.39 g was acquired. This crude extract was labelled 
CVEXT001. 
8.2.2 Processing and isolations 
To the dried CVEXT001 was then added 300 mL of water, which had been acidified to pH3 using 
H2SO4. The reasoning behind this was that the alkaloids present in CVEXT001 would be protonated, 
and transformed into their quaternary ammonium salt forms, which would have a higher affinity for 
aqueous solution. The acidified solution was found to have a pH of 6. This indicated that there were 




supporting the presence of alkaloids. The solution was then acidified further to a pH of about 4 using 
H2SO4 and was sonicated to evenly disperse the contents in solution.  
The acidified aqueous CVEXT001 was then extracted with hexane (3×100 mL). Because the 
alkaloids were in salt form, they would remain in the aqueous layer, and the hexane would remove 
compounds that were not of interest. The aqueous layer after extraction with hexane was labelled 
CVAq1. 
CVAq1 was then exhaustively extracted with a more polar solvent, ethyl acetate (EtOAc) (7×100 
mL), to further remove any unwanted compounds. The aqueous layer was then labelled CVAq2. The 
aqueous extract remained at a pH of 4 throughout the extractions with both organic solvents.  
CVAq2 was then basified to pH 9 with aqueous sodium hydroxide (NaOH). This was done to 
deprotonate the alkaloids present, converting them to their free base forms, which have a higher 
affinity for organic solvents. Following this, a continuous liquid/liquid extraction apparatus (please 
see Appendix A for apparatus) was used to extract CVAq2 with EtOAc for 24 hours, during which 
time, the alkaloids present in the aqueous layer should have moved into the organic layer. The EtOAc 
extract was labelled CVAlk.EXT, to infer that it was the extract containing alkaloids. The acquired 
mass after drying under high vacuum was 3.59 g.  
8.2.2.1 Isolation of lycorine 19 
Having obtained an extract containing the alkaloid content of the Crinum variabile plant material, a 
few solvent systems were tested using TLC in order to find one that effectively separated the 
components within the extract. The solvent system EtOAc:MeOH:H2O (85:10:5) separated the 
constituents most effectively (Figure 8.2.2). An attempt was then made to dissolve CVAlk.EXT in 
MeOH with the intention of proceeding with chromatographic separation methods. It was noted that 
a light-coloured solid did not dissolve in the MeOH. This was filtered off, washed with MeOH, dried 
under high vacuum, and weighed. This solid, labelled AlkEXT.S, was an off-white powder-like 
substance, and had a mass of 0.934 g. It was decided that a crude NMR spectrum would be beneficial, 
so this was carried out using DMSO-d6 as a solvent (the material was insufficiently soluble in MeOH, 
CHCl3, and other organic solvents). The resulting spectrum corresponded to that of pure lycorine 19 






Figure 8.2.1 – The numbered chemical structure of lycorine 19. 
 
Table 8.1 – 1H NMR spectroscopy chemical shifts for lycorine 19. Literature values cited from Likhitwitayawuid et al. (1993).76 
Proton Lit. Acquired 
H-1 4.27 br s 4.25 br s 
H-2 3.97 br s 3.95 br s 
H-3 5.37 br s 5.34 br s 
H-4a 2.60 d 2.58 d, J=10.3 Hz 
H-6α 3.32 d 3.28 (overlap w/water signal) 
H-6β 4.02 d 3.99 d, J=14.2 Hz 
H-7 6.68 s 6.65 s 
H-10 6.81 s 6.78 s 
H-10b 2.50 m Behind solvent peak (2.48) 
H-11 (2H) 2.44 m 2.44 m (solvent peak overlap) 
H-12α 2.19 ddd 2.18 ddd, J=8.6, 8.6, 8.6 Hz 
H-12β 3.19 dd 3.17 m 
O-CH2-O 5.95 s 5.93 dd, J=5.6, 0.9 Hz 
1-OH 4.79 br d 4.74 d, J=4.2 Hz 
2-OH 4.90 br s 4.84 d, J=6.2 Hz 
Solvent DMSO-d6 DMSO-d6 
 
Table 8.2 - 13C NMR spectroscopy chemical shifts of lycorine 19. Literature values cited from Likhitwitayawuit et al. (1993).76 
Carbon Lit. Acquired Δδ 
1 70.21 70.20 -0.01 
2 71.72 71.71 -0.01 
3 118.48 118.46 -0.02 
4 141.68 141.65 -0.03 
4a 60.83 60.80 -0.03 
6 56.73 56.71 -0.02 
6a 129.75 129.74 -0.01 




8 145.20 145.18 -0.02 
9 145.65 145.63 -0.02 
10 105.06 105.04 -0.02 
10a 129.57 129.57 0 
10b 40.18 40.16 -0.02 
11 28.13 28.11 -0.02 
12 53.31 53.29 -0.02 
OCH2O 100.57 100.54 -0.03 
Solvent DMSO-d6 DMSO-d6  
 
The assignments shown were verified using two-dimensional NMR (2D NMR) spectroscopic 
experiments including COSY, HSQC and DEPT experiments (please see Appendix A for spectra), 
as well as by comparison to literature data. The 13C NMR data presented in Table 8.2 show 
consistently minor chemical shift differences to those presented in the literature, though these 
differences are small enough to be inconsequential. 
MS analysis showed a [M+H]+ ion at 288.1241, correlating to the expected molecular formula of 
C16H17NO4 (after removal of a proton to account for ESI +ve). The calculated mass for [M+H]
+ was 
288.1236, with a difference between calculated and acquired masses of 1.7 ppm. Please see Table 
8.17 for fragmentation information.  
Optical rotation experiments resulted in an [𝛼]𝐷
20 of -61.5°, c=1, DMSO (lit. [𝛼]𝐷
22 of −63.2°, c=0.83, 
EtOH77; [𝛼]𝐷
20 of -62°, c=0.1, EtOH76,78 ). The acquired value is in good agreement with those reported 
in literature. 
Thus, the isolation of 934 mg of lycorine 19 was carried out in a very straightforward manner. This 
mass of lycorine 19 correlates to 0.67% of the dry bulb mass (6.7 g/kg). Further on in this chapter, 
the isolation of additional lycorine 19 will be noted during the processing of S1 (in the sample PP1_2), 
as well as in the sample PP2_1. Lycorine 19 was present in PP1_2 with a mass of 42.4 mg. This mass 
of lycorine 19 was obtained from 100 mg of S1. Given that the total mass of S1 was 297 mg, the total 
mass of lycorine present in S1 was 42.4 ×
297 (total mass of 𝐒𝟏)
100
= 125.9 mg. The lycorine 19 present 
in PP2_1 had a mass of 53.2 mg. These masses can be added to the initially isolated mass of lycorine, 
resulting in a total mass of 1.113 g (0.80% of dry bulb mass – 8.0 g/kg) 
An important point to note is that the isolated mass of lycorine 19 does not encompass the entirety of 
the lycorine 19 present in the original extract (CVAlk.EXT). Some lycorine 19 was also present in 
further fractions (such as in fractions of C3.1), based on TLC evidence. Unfortunately, time 




reported. It can, however, be assumed that total recovery of lycorine 19 from C. variabile would 
likely result in a yield exceeding 0.80% of the dry bulbs mass. Though this is greater than the values 
reported for many species,79,80 significantly greater yields have been reported for Sternbergia lutea, 
with one study reporting a yield of over 2% from dry bulb mass.79,81  
8.2.2.2 Isolation of 1,2-O,O-diacetyllycorine 21 
Having identified AlkEXT.S, the mother liquor from which it was acquired (AlkEXT.F) was 
subjected to further fractionation by chromatographic means. The first step in this regard was the 
implementation of a relatively short silica column (i.e. a silica plug), in order to crudely fractionate 
based on polarity. A consideration when deciding to use as little silica as possible for this initial 
separation was that compounds can bind irreversibly to silica.72 Given that the entirety of the sample 
was being used, it was considered safer to avoid the large quantities of silica that would have been 
required for a column on this scale.  
Before loading AlkEXT.F onto the silica plug (P1), it had to be dissolved and loaded onto silica. 
MeOH was used for this, since the compounds present had previously dissolved in this solvent. The 
sample was then dry loaded and eluted from P1. Twenty-six fractions of 700 mL each were 
acquired (labelled P1_1-26), with eluents ranging from non-polar 100% hexane to highly polar 
EtOAc:MeOH:H2O (70:20:10). For every solvent system applied to the plug, a single large fraction 
was collected. A final wash was carried out with EtOAc:MeOH:Et3N (50:20:30), in the hopes that 
the basic Et3N would bind to and deactivate the silica, helping to wash off any sample still on the 
plug.  
In order to evaluate the results of P1, a large TLC plate was spotted with each of the 26 fractions on 
the baseline. It was then placed in a PLC chamber to develop, using EtOAc:MeOH:H2O (85:10:5) 
(henceforth to be referred to as solvent system A) a photograph of this TLC plate is shown below 





Figure 8.2.2 - TLC plate representing the separation acquired from P1. 
The stain used to visualize the spots on this plate was Dragendorff’s reagent, which is selective for 
alkaloids82. As can be seen in Fig. 6.3, P1 provided a reasonable separation by polarity, and produced 
fractions which offered some level of grouping of the alkaloids present in AlkEXT.F. This allowed 
for the selection of fraction that could be grouped for further separation steps.  
The first such group to be selected contained fractions 1-6 from P1 (P1_1-6), which were recombined. 
This group contained a few relatively non-polar alkaloids, having eluted between 100% hexane and 
1:1 hexane:EtOAc during P1. It was decided that a column would be the best way to obtain the major 
component of the group, and thus the sample (weighing 348 mg) was loaded onto a silica column 
(labelled C1), and a hexane/EtOAc gradient was applied for elution. The fractions (7 mL) of C1 were 
monitored by TLC, and based on the results, were divided into ten fraction groups (C1_1-10). The 
majority of the mass eluted was present in C1_8, which contained 221 mg of a white crystal after 
drying under high vacuum (grouped due to the presence of a single spot on TLC). This mass 
corresponds to 0.16% of the dry bulb mass. An aliquot of this sample was dissolved in chloroform-d 
and subjected to 1H and 13C NMR spectroscopic analysis, which resulted in spectra corresponding to 
those of pure 1,2-O,O-diacetyllycorine 21 (Figure 8.2.3). Table 8.3 and Table 8.4 illustrate the 
corresponding assignments based on literature values. 
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Figure 8.2.3 – The numbered chemical structure of 1,2-O,O-diacetyllycorine 21. 
Table 8.3 - Proton chemical shifts of 1,2-O,O-diacetyllycorine 21. Literature values cited from Lamoral-Theys et al (2009).83 
Proton δ (ppm) Lit. δ (ppm) Acquired 
H-1 5.75 s 5.73 br s 
H-2 5.27 s 5.24 br s 
H-3 5.45 s 5.51 br s 
H-4a 2.89 d 2.76 d, J=10.4 Hz 
H-6α 3.55 d 3.52 d, J=14.3 Hz 
H-6β 4.18 d 4.15 d, J=14.1 Hz 
H-7 6.76 s 6.74 s 
H-10 6.59 s 6.56 s 
H-10b 2.79 d 2.87 d, J=10.4 Hz 
H-11 (2H) 2.67 m 2.65 m 
H-12α 2.42 m 2.39 ddd, J=8.8, 8.8, 8.8 Hz 
H-12β 3.38 m 3.36 m 
O-CH2-O 5.94 s 5.93 s 
1-O-Ac (Me) 1.97 s 1.94 s 
2-O-Ac (Me) 2.09 s 2.07 s 
Solvent CDCl3 CDCl3 
 
Table 8.4 - Carbon chemical shifts of 1,2-O,O-diacetyllycorine 21. Literature values cited from Lamoral-Theys et al. (2009).83 
Carbon δ (ppm) Lit. δ (ppm) Acquired Δδ 
1 69.3 69.40 0.1 
2 71.0 71.05 0.05 
3 113.9 113.95 0.05 
4 146.5 146.57 0.07 
4a 61.3 61.38 0.08 
6 58.9 57.05 -1.85 
6a 129.5 129.57 0.07 
7 105.1 105.20 0.1 




9 146.2 146.27 0.07 
10 107.4 107.45 0.05 
10a 126.6 126.71 0.11 
10b 40.6 40.68 0.08 
11 28.7 28.82 0.12 
12 53.9 53.77 -0.13 
OCH2O 101.0 101.11 0.11 
1-O-Ac (Me) 20.9 21.08 0.18 
2-O-Ac (Me) 21.3 21.28 -0.02 
1-O-Ac (CO) 172.3 170.12 -2.18 
2-O-Ac (CO) 171.8 169.89 -1.91 
Solvent CDCl3 CDCl3  
 
These assignments were confirmed using 2D NMR spectroscopic experiments including COSY, 
HSQC, HMBC, and DEPT (please see Appendix A for spectra), in addition to comparison with 
literature data. Of the 13C NMR peak shift differences (Δδ) presented in Table 8.4, some values are 
of note. C-6 and C-12, and both carbonyl signals, show lower values than those in the literature, while 
most other peaks are slightly higher when compared. Additionally, the shifts of C-6 and the carbonyl 
peaks differ by a greater margin than the majority of the other peaks. Reasons for these observations 
may include the possible presence of impurities in the NMR sample of 21 and differences in the water 
content of deuterated solvents used (water may interact with the carbonyl oxygens, affecting their 
corresponding carbons). Despite the observed differences, the evidence available is sufficient that the 
identity of 21 is assigned with relative confidence. 
One additional difference with literature values can be noted in the 1H NMR spectrum signals for 
protons H-4a and H-10b. The signal at 2.76 ppm was assigned as H-4a and that at 2.87 ppm was 
assigned as H-10b, while these assignments were reversed in the report by Lamoral-Theys et al. 
(2009)83. The reason the assignments were made this way was evident in the COSY spectrum, in 
which the signal at 2.87 ppm was coupled to that for H-1. This coupling would only be noted for H-
10b, and not for H-4a, and so the signals reported here are more consistent with the structure of 21.  
MS analysis showed a [M+H]+ ion at 372.1447, correlating to the expected molecular formula of 
C20H21NO6 (after removal of a proton to account for ESI +ve). The calculated mass for [M+H]
+ was 
372.1447, with no difference between calculated and acquired masses. Please see Table 8.17 for 
fragmentation information.  
Optical rotation experiments resulted in an [𝛼]𝐷
20 of +23.6°, c=1, CHCl3 (lit. [𝛼]𝐷
25 of +26.8°, c=1.22, 
CHCl3
84; [𝛼]𝐷




8.2.2.3 Isolation of 2-O-acetyllycorine 22 
After the analysis of the C1_8 fraction group, attention was drawn to the following fraction group of 
the same column (fraction group C1_9). The reason for this was the presence of a crystalline 
substance in C1_9 which was visible in the sample vial. After ensuring that the sample responded to 
Dragendorff’s reagent, and did not have the same Rf as 1,2-O,O-diacetyllycorine 21, it was decided 
that a silica gel column should be utilised for this compound’s purification. Based on the TLC 
performance of some test solvent systems, it was decided that this column (labelled C1.1) should be 
executed using a DCM/MeOH gradient. 20 mL fractions were collected, analysed by TLC, and 
combined, resulting in five groups of fractions (C1.1_1–5). The compound of interest was present in 
the third group (C1.1_3), with a mass of 45.2 mg. A portion of this sample was used for NMR 
spectroscopic analysis, which resulted in the spectra for 2-O-acetyllycorine 22 (Figure 8.2.4). Table 
8.5 and Table 8.6 illustrate the corresponding assignments based on literature values. 
 
Figure 8.2.4 - The numbered chemical structure of 2-O-acetyllycorine 22. 
Table 8.5 - Proton shifts of 2-O-acetyllycorine 22. Literature values cited from Toriizuka et al. (2008).85 
Proton δ (ppm) Lit. δ (ppm) Acquired 
H-1 4.52 s 4.37 br s 
H-2 5.32 m 5.18 m 
H-3 5.47 m 5.35 br s 
H-4a 2.79 br d 2.67 d, J=10.4 Hz 
H-6α 3.53 d 3.35 water peak overlap 
H-6β 4.14 d 4.03 d, J=14.2 Hz 
H-7 6.60 s 6.68 s 
H-10 6.81 s 6.86 s 
H-10b 2.71 br d 2.43 d, J=10.5 Hz 
H-11 (2H) 2.65 m 2.51 m (solvent peak overlap) 
H-12α 2.38 ddd 2.24 ddd, J=8.6, 8.6, 8.6 Hz 
H-12β 3.37 ddd 3.21 dd, J=7.7, 7.7 Hz 
O-CH2-O 5.94, 5.92 two ds 5.94 dd, J=11.0, 0.8 Hz 




Solvent CDCl3 DMSO-d6 
 
Table 8.6 - Carbon shifts of 2-O-acetyllycorine 22. Literature values cited from Toriizuka et al. (2008).85 
Carbon δ (ppm) Lit. δ (ppm) Acquired 
1 69.4 67.57 
2 73.7 73.80 
3 113.6 113.81 
4 146.0 145.85 
4a 60.7 61.0 
6 58.3 57.03 
6a 127.0 128.88 
7 107.7 107.50 
8 146.4 146.14 
9 146.6 146.65 
10 104.6 105.79 
10a 130.2 130.11 
10b 41.8 41.69 
11 29.4 28.69 
12 57.0 53.60 
O-CH2-O 101.0 101.08 
2-O-Ac (Me) 21.3 21.50 
2-O-Ac (CO) 170.6 170.15 
Solvent CDCl3 DMSO-d6 
 
The acquired assignments were verified using 2D NMR spectroscopic experiments including HSQC, 
HMBC, COSY and DEPT (please see Appendix A for spectra), as well as by comparison to spectra 
in the literature. It should be noted that the spectra were acquired using DMSO-d6 as a solvent, which 
explains the difference in chemical shift noted for some of the protons when compared to literature 
values. Chemical shift differences for the 13C NMR peaks are not presented for this compound, as a 
different solvent was used for NMR analysis of 22. The reason for this was that solubility of 22 in 
CHCl3 was somewhat problematic during this investigation.  
MS analysis showed a [M+H]+ ion of mass 330.1346, correlating to the expected molecular formula 
of C18H19NO5 (after removal of a proton to account for ESI +ve). The calculated mass for [M+H]
+ 
was 330.1341, with a difference between calculated and acquired masses of 1.5 ppm. Please see Table 




Optical rotation experiments resulted in an [𝛼]𝐷
20 of +8.8°, c=0.77, MeOH (lit. [𝛼]𝐷
25 of +22.4, c=0.2, 
CHCl3
83). 
8.2.2.4 Isolation of 1-O-acetyllycorine 23 
Focus was then turned to the second fraction group of P1. This group consisted of fractions P1_7-9 
and contained a compound of moderate polarity as the major component, as can be seen in Figure 
8.2.2 above. Given that the mass of P1_7-9 was somewhat higher than would be adequate for a PLC 
plate, a silica gel column was chosen once again as the separation method for purification. After 
testing for optimal solvent elution systems, the 286.2 mg of sample was dry loaded, and the column 
(labelled C2) was eluted with an isocratic mobile phase of 100% EtOAc. The 20 mL fractions 
obtained were divided into four groups (C2_1-4), and it was noted that the third of these (C2_3) 
contained the major component, though it was still impure. Thus, a PLC plate was selected for further 
purification. Fraction C2_3 was loaded in its entirety onto the plate (labelled PP0), which was placed 
in a chamber containing EtOAc to develop.  
Allowing the solvent front to run up the plate a single time, however, proved insufficient for the 
effective separation of the sample’s components. Thus, the process was repeated until satisfactory 
separation of bands on the plate was observed (a total of seven repetitions). The progress of this 
process was observed under UV light (254 nm). When complete, the plate contained three visible 
bands under UV, all of which were scraped off and collected. The compounds were removed from 
the silica by washing with organic solvents (namely DCM and EtOAc). These bands were labelled 
PP0_1-3, ordered by polarity such that PP0_1 was the band with the highest Rf (this ordering 
convention was maintained for all separations).  
It was found that the majority of the mass of the sample was present in the second band from this 
plate, PP0_2. This sample (178.5 mg) was dissolved in CDCl3 and subjected to NMR spectroscopic 
analysis, providing spectra correlating to those of pure 1-O-acetyllycorine 23 (Figure 8.2.5). Table 
8.7 and Table 8.8 illustrate the corresponding assignments based on literature values. 
 




Table 8.7 - Proton shifts of 1-O-acetyllycorine 23. Literature values cited from Toriizuka et al. (2008).85 
Proton δ (ppm) Lit. δ (ppm) Acquired 
H-1 5.64 br s 5.55 br s 
H-2 4.24 m 4.13 (overlap w/H-6β) 
H-3 5.56 s-like 5.52 m 
H-4a 2.75 br d 2.73 d, J=10.5 Hz 
H-6α 3.53 d 3.48 d, J=14.0 Hz 
H-6β 4.15 d 4.13 (overlap w/H-2) 
H-7 6.58 s 6.55 s 
H-10 6.71 s 6.59 s 
H-10b 2.87 br d 2.83 d, J=10.5 Hz 
H-11 (2H) 2.65 m 2.59 m 
H-12α 2.40 ddd 2.35 ddd, J=8.9, 8.9, 8.9 Hz 
H-12β 3.37 m 3.33 ddd, J=4.7, 4.7, 9.2 
O-CH2-O 5.92 s-like 5.89 s 
1-O-Ac (Me) 1.95 s 1.91 s 
Solvent CDCl3 CDCl3 
 
Table 8.8 - Carbon shifts of 1-O-acetyllycorine 23. Literature values cited from Toriizuka et al. (2008).85 
Carbon δ (ppm) Lit. δ (ppm) Acquired Δδ 
1 72.6 72.66 0.06 
2 69.6 69.35 -0.25 
3 117.2 117.38 0.18 
4 144.1 143.57 -0.53 
4a 61.5 61.55 0.05 
6 56.8 56.77 -0.03 
6a 127.0 127.01 0.01 
7 107.3 107.25 -0.05 
8 146.2 146.18 -0.02 
9 146.5 146.44 -0.06 
10 104.9 104.84 -0.06 
10a 129.3 129.19 -0.11 
10b 39.3 39.12 -0.18 
11 28.6 28.49 -0.11 
12 53.6 53.65 0.05 
OCH2O 100.9 100.91 0.01 
1-O-Ac (Me) 21.0 21.03 0.03 
1-O-Ac (CO) 170.8 170.74 -0.06 





Again, HSQC, HMBC, COSY and DEPT experiments were used to verify these assignments, in 
addition to comparison with literature data (please see Appendix A for spectra). The 13C NMR peak 
shift differences presented in Table 8.8 show small differences when compared to literature values, 
with some being slightly higher and some slightly lower than those reported. The differences remain 
relatively minor despite the differing signs, and so are not of great concern, though the Δδ value for 
C-4 should be noted as a slight outlier. The possible presence of impurities in the NMR sample of 23 
may explain the observed differences, or perhaps similar minor error in the literature value could be 
responsible. The differences observed are sufficiently small that the identity assigned is maintained 
with relative confidence.  
MS analysis showed a [M+H]+ peak at 330.1346, correlating to the expected molecular formula of 
C18H19NO5 (after removal of a proton to account for ESI +ve). The calculated mass for [M+H]
+ was 
330.1341, with a difference between calculated and acquired masses of 1.5 ppm. Please see Table 
8.17 for fragmentation information.  
Optical rotation experiments resulted in an [𝛼]𝐷
20 of -73.6°, c=1, CHCl3 (lit. [𝛼]𝐷




20 values acquired for 1-O-acetyllycorine 23 and 2-O-acetyllycorine 22 are evidence 
supporting the correct differentiation of the two compounds, as they rotate light in opposite directions, 
and the acquired values support their respective assignments.  
Another telling virtue for the differentiation between 1-O-acetyllycorine 23 and 2-O-acetyllycorine 
22 was evident in their H1 NMR spectra. In 1-O-acetyllycorine 23, H-1 of lycorine 19 (appearing as 
a broad single peak at δ 4.25) was strongly deshielded to a single peak at δ 5.55 while H-2 of lycorine 
19 (originally a broad single peak at δ 3.95) underwent a shielding effect to a single peak at δ 4.13 
due to the anisotropic shielding cone of the adjacent ester carbonyl. In the corresponding case of  2-
O-acetyllycorine 22, the broad single peak of H-2 of lycorine 19 at δ 3.95 was strongly deshielded to 
a single peak at δ 5.18, while H-1 of lycorine 19 – originally a broad single peak at δ 4.25 – was 
shielded in 2-O-acetyllycorine 22 to a single peak at δ 4.37, again by the shielding cone of the adjacent 
ester carbonyl functional group.  
At this point, it had to be noted that the only compounds isolated had been lycorine 19 and acetylated 
versions thereof. This raised the concern that the extraction process (carried out at relatively high 
temperatures in EtOAc) could have been responsible for the formation of the acetylated analogues as 




amount of lycorine 19 was heated under reflux in EtOAc for 24 hours, to determine whether these 
conditions would be capable of acetylation of the -OH groups. After a period of 24 hours, TLC 
showed only one spot, with a Rf corresponding to that of lycorine 19. This showed that reflux of 
lycorine in EtOAc under the same conditions as the extraction did not acetylate it, which is evidence 
that the acetates were produced in the plant itself, rather than having been generated as a result of the 
extraction process.  
8.2.2.5 Isolation of CV3 – (6-epi)haemanthidine (24, 25) 
Having confirmed the validity of the compounds isolated thus far, the process of purification of 
further compounds was continued. This recommenced with the third fraction group from P1, which 
was the combination of fractions 10, 11 and 12 (P1_10-12), and as can be seen in Figure 8.2.2, 
contained a Dragendorff-positive compound as the major component. Thus, these fractions were 
combined for further processing. Based on Figure 8.2.2, it may seem as though only one compound 
was present in these fractions. However, further TLC analysis showed the presence of two 
Dragendorff-positive compounds (amongst some other impurities visible under UV light), one of 
which had an Rf corresponding to that of lycorine 19. The reason for the presence of the lycorine 19 
spot not being immediately apparent in Figure 8.2.2 is that it does not respond strongly to 
Dragendorff’s reagent, and takes some time to develop a darker colour in response to the stain.  
During the process of recombining P1_10-12, a white solid did not dissolve when MeOH was added 
to the samples. The fractions were recombined regardless, and the solid that did not dissolve was 
filtered off and washed with cold MeOH. The mass of this white powder (labelled S1) was 297 mg. 
A 30 mg sample of this was dissolved in DMSO-d6, and subjected to NMR spectroscopic analysis, 
resulting in spectra which clearly indicated a mixture of at least two compounds. Thus, further 
purification steps were necessary.  
The white powder collected still showed two spots on TLC when stained with Dragendorff’s reagent, 
one corresponding to lycorine 19, and the other with a slightly higher Rf. The two spots were well 
resolved when solvent system A was used to develop the TLC. It was thus decided that a viable 
separation method would be the use of a PLC plate. Thus 100 mg of S1 was dissolved in a minimum 
amount of MeOH (the addition of a small amount of H2O and slightly heating the sample assisted in 
dissolving it) and streaked onto a PLC plate (labelled PP1), which was developed in solvent system 
A. A single development run was sufficient to resolve the bands, and they were scraped off and 
isolated by washing the silica with EtOAc:MeOH (8:2). The band above that corresponding to 
lycorine 19 (labelled PP1_1) had a mass of 44.8 mg after drying under high vacuum.  PP1_2 produced 




PP1_1, as the unknown substance, was naturally of higher interest and was thus the centre of focus. 
NMR spectroscopic analysis of this material still produced what appeared to be impure NMR spectra, 
despite only one spot being visible on TLC using Dragendorff’s reagent. In order to address this 
challenge, the solvent system was optimised using test TLC experiments, and it was decided that a 
DCM/MeOH gradient would be ideal for purification. A column (C3) was wet loaded with PP1_1 in 
DCM, and eluted using 5-10% MeOH in DCM. TLC was used to analyse each of the fractions eluting 
from C3, and only fractions which showed a single correlating spot under both UV light and 
Dragendorff’s reagent were combined to generate the sample CV3 (20.8 mg).  
1H and 13C NMR spectroscopic analysis of CV3 still provided spectra that indicated a mixture of 
compounds, suggesting the presence of two compounds with identical Rf values on silica. One note 
made while considering the 13C NMR spectrum of the sample was that there appeared to be smaller 
“partner” peaks residing at nearby chemical shifts to those of many of the more intense peaks. This 
led to the suggestion that the sample may have been a mixture of two isomers, but further data was 
required before this assumption could be made. Separation of the components would, of course, be 
the most favourable outcome.  
Several optimisation methods were attempted, including test TLCs using a number of solvent systems 
as well as TLCs with alumina (Al2O3) as a stationary phase, but all continued to show only a single 
spot, and thus failed to separate the coeluting compounds. An orthogonal separation method would 
be that of reversed phase (RP) chromatography, and HPLC analysis of the sample was selected as a 
possible means of separating the components present in CV3. This separation method can also be 
coupled to high-resolution mass spectrometry (HRMS), which could assist in providing some 
structural information on eluting compounds. Thus, CV3 was subjected to HPLC-HRMS analysis 
using a RP C18 column.   
The resulting total ion chromatograms (TICs) showed only one major peak, with some small minor 
peaks (one with a mass of 288, correlating to lycorine (19) [M+H]+). Several optimisations of the 
HPLC method were attempted, but separation of the major peak into multiple components was not 
achieved. This showed that the compounds in CV3 were of sufficiently similar chemical structure 
that even a high-performance separation technique was not capable of resolving them. The MS data 
provided by the HPLC-HRMS analysis of CV3 provided some useful information, as data including 
fragmentation information (acquired using MS) was obtained.  
The MS data showed a base peak ion (BPI) of m/z 318.1340. When using the MS analysis software 
Masslynx©, a tool is available which allows for the prediction of the elemental composition when 




composition using natural isotope abundances and reports a percentage which indicates the 
confidence with which each composition can be assigned. Elemental composition analysis of the peak 
of mass 318.1340 reports a molecular formula of C17H20NO5 with a confidence of 99.76%, and a 
difference of 0.3 ppm between the calculated and acquired masses (calc. 318.1341, acq. 318.1340). 
Given that this data was acquired in positive ionisation mode, removal of a single proton gives the 
molecular formula of the major component of CV3 as C17H19NO5.  
To gain further insight, the mass fragments acquired from this peak were also reviewed, a discussion 
of which will follow the presentation of NMR spectroscopic data.  
With the information obtained from HPLC and HRMS analyses, the NMR spectra for CV3 were 
revisited with a more informed perspective. Amaryllidaceae alkaloids with the molecular formula 
C17H19NO5 were researched, and the 
1H NMR spectra reported for these were compared to that of 
CV3. Promising results were found when a mixture of haemanthidine 24 and 6-epihaemanthidine 25 
(Figure 8.2.6) was proposed.  
 




Table 8.9 - The 1H NMR spectroscopic peaks of CV3 and those reported for haemanthidine (24) and 6-epihaemainthidine (25). Literature values are cited from Bastida et al. (2006),87 with an additional 
report from Nishimata and Mori (1998)88, which indicates peak integrals.  
 Bastida et al.87 Nishimata & Mori88 CV3 peaks 
Proton number Haemanthidine (24) 6-epihaemanthidine (25) (−)-haemanthidine “6-epihaemanthidine (25)” Haemanthidine (24) 6-epihaemanthidine (25) 
1 6.33 d 
6.37-6.40, 2H, m 6.16-6.31, 2H, m 
2 6.27 dd 
3 3.85 m 3.87-3.97, 2.55H, m 3.86-4.12, 2.5H, m 
4α 2.36 ddd 2.21 ddd 2.33, 0.45H, dt 2.18, 0.55H, dt 
2.09-2.37, 2.5H, m 
4β 2.12 ddd 2.00 ddd 2.10, 0.45H, dd 2.03, 0.55H, dd 
4a 3.56 dd 3.20 m 3.59, 0.45H, dd 3.78, 0.5H, dd, J=12.2, 5.8 Hz 
6α 5.02 s 5.04, 0.55H, s 5.05, 0.5H, s 
6β 5.69 s 5.69, 0.45H, s 5.64, 0.5H, s 
7 6.94 s 6.79 s 6.98, 0.45H, s 6.83, 0.55H, s 7.00, 0.5H, s 6.84, 0.5H, s 
10 6.70 s 6.73 s 6.77, 0.45H, s 6.80, 0.55H, s 6.76, 0.5H, s 6.78, 0.5H, s 
11 3.92 m 3.87-3.97, 2.55H, m 3.86-4.12, 2.5H, m 
12 endo 4.20 dd 3.30 m 4.20, 0.45H, dd 3.34, 0.55H, m 
4.24, 0.5H, dd, 
J=14.2, 6.7 Hz 
3.26-3.52, 4.5H, m 
12 exo 2.96 dd 3.20 m 2.94, 0.45H, dd 3.25, 0.55H, dd 3.04, 0.5H, br d, J=14.1 Hz 
OCH2O 5.83 (2d) 5.86 (2d) 5.90-5.93, 2H, m 5.90-5.97, 2H, m 
OMe 3.32 s 3.28 s 3.38, 1.35H, s 3.35, 1.65H, s 3.26-3.52, 4.5H, m 




Interestingly, Nishimata and Mori (1998)88 report all their data in the above table as a single list of 
peaks, as the spectral data for  (−)-haemanthidine. There are, of course, too many peaks to belong to 
just one isomer, and the spectral data shown correlates fairly well with a mixture of the two 
diastereomers, as can be seen upon comparison with the data from Bastida et al.,87 which reports data 
based on a mixture of the diastereomers.89 As is evident, the 1H NMR spectrum of CV3 shows 
evidence supporting the identification of the sample as a mixture of haemanthidine 24 and 6-
epihaemanthidine 25, though some differences in chemical shift values must be noted.  
The presence of 6-epihaemanthidine 25 was substantiated by the presence of additional peaks which 
cannot be assigned to haemanthidine 24. In particular, the four singlets at 6.76-7.00 ppm are strong 
evidence supporting a mixture, as a single epimer would only produce two singlets in this region 
corresponding to protons 7 and 10.  
The spectra of PP1_1 were reviewed at this point, and it was found that the sample was almost 
identical to CV3, with some very minor impurity peaks. Thus, it can be surmised that the mass of 
CV3 present in 100 mg of S1 was 44.8 mg, meaning that the total mass of CV3 in S1 (297 mg) was 
44.8 ×
297 (total mass of 𝐒𝟏)
100
= 133.1 mg.  
As previously mentioned, the 13C NMR spectrum of CV3 was the first noted indicator that the sample 
may have been a mixture of isomers. With the additional information provided by the 1H spectrum, 
as well as the HPLC-HRMS results, this notion is reinforced. The chemical shifts in the 13C NMR 
spectrum of CV3 also correlated with those reported in literature for (6-epi)haemanthidine. 
Table 8.10 - 13C shifts acquired for both epimers of haemanthidine (24 and 25), reported with the shifts acquired for CV3. Literature 
values are cited from Bastida et al.87 
 13C peaks of haemanthidine87 
13C peaks of CV3 Δδ Carbon 
number 
Haemanthidine 24 6-epihaemanthidine 25 
1 126.7 126.3 123.12 122.93 -3.58 -3.37 
2 132.3 132.8 134.6 135.85 2.3 3.05 
3 72.5 72.5 75.95 75.64 3.45 3.14 
4 27.8 27.6 29.69 29.41 1.89 1.81 
4a 61.6 56.2 64.83 59.56 3.23 3.36 
6 85.8 88.4 85.51 88.06 -0.29 -0.34 
6a 129.2 127.8 128.78 127.34 -0.42 -0.46 
7 108.2 109.5 108.31 109.54 0.11 0.04 
8 146.5 146.4 146.73 146.56 0.23 0.16 
9 147.4 147.7 147.6 147.83 0.2 0.13 




10a 134.7 135.8 136.28 136.46 1.58 0.66 
10b 50.7 50.3 50.45 50.84 -0.25 0.54 
11 79.2 78.3 79.01 78.13 -0.19 -0.17 
12 52 57.8 51.84 57.7 -0.16 -0.1 
O-CH2-O 101 101 101.12 0.12 
-OMe 56.8 56.5 55.95 56.01 -0.85 -0.49 
Solvent CDCl3 CDCl3  
 
The differences noted in the 13C NMR chemical shifts are significant, especially for carbons C-1 to 
C-4a, as well as C-10a and the methoxy carbon. The differing signs of the Δδ values are also a cause 
for concern, as this indicates that the shift is not constant in nature (shielding/deshielding). These 
varying results may be due to differing ratios of the diastereomers, or perhaps due to the presence of 
some impurities in CV3. Despite the inconsistencies in the available data, (6-epi)haemanthidine (24, 
25) remains the most viable identification of CV3 which can be suggested, to the best of our 
knowledge. 
Having acquired data that indicated the identity of CV3 as a mixture of haemanthidine epimers (24 
and 25), the mass fragments acquired from the MS/MS analysis of the sample could be interpreted 
with some additional insight. Figure 8.2.7 below shows the obtained mass spectrum of the primary 
peak observed during HPLC-MS/MS analysis of CV3.  
  
Figure 8.2.7 – MS/MS spectrum of CV3, showing fragmentation information. 
In a book chapter by Bastida et al. (2006),87 the fragmentation of haemanthamine-type alkaloids is 
discussed, and the information contained therein provided useful direction when attempting to explain 
some of the observed peaks. In fragmentation mechanisms shown by Bastida et al. (2006)87 for 





applicable for corresponding mechanisms in haemanthidine 24. For example, the peaks in the MS 
spectrum of haemanthamine indicate the loss of a CH2=NMe fragment.
87 The analogous loss for 
haemanthidine 24 would be that of CH(OH)=NMe (due to the presence of the 6-hydroxy group in 
haemanthidine 24). As can be seen in Table 8.11, some peaks present in the spectrum can be 
tentatively assigned to the loss of this fragment (amongst others). 
Table 8.11 - Tentative explanations for some observed fragment ions in the MS/MS spectrum of CV3. 
m/z Mass loss Possible fragments lost 
318 0 None ([M+H]+) 
300 18 H2O 
286 32 MeOH, CHO, CH2O 
268 50 MeOH, H2O 
250 68 MeOH, H2O, H2O 
227 91 CH(OH)=NMe, MeOH 
224 94 CH(OH)=NMe,  
220 98 MeOH, H2O, H2O, CH2O 
209 109 CH(OH)=NMe, MeOH, H2O 
199 119 MeOH, CHO, CH2NH, CHO 
169 149 MeOH, CHO, CH2NH, CHO, CH2O 
 
Important to note is that no elucidation attempts regarding mechanisms for these suggested mass 
losses were made. Thus, the data presented in Table 8.11 is tentative and limited to only some of the 
peaks in the spectrum. Further investigations regarding this mass spectrum are necessary before 
conclusions can be drawn. 
The mass fragments noted in Table 8.11 are in good agreement with those expected for haemanthidine 
24, and the fragments acquired for 6-epihaemanthidine 25 will likely be analogous to those of its 
epimer, which infers that this mass spectrum agrees with the notion that CV3 is a mixture of the two 
epimers. Difficulty was faced in finding a literature source in which ESI+ve was utilised as an 
ionisation method when obtaining the fragmentation pattern of haemanthidine 24. Thus, comparison 
of the acquired data with literature data could not occur. Given that this sample was a diasteriomeric 
mixture, optical rotation experiments were not carried out. 
Further attempts to separate the two isomers were made, which included the acetylation of CV3, in 
the hopes that increasing the size of the moiety at the diastereomeric centre would generate 
sufficiently differing compound conformations to allow for separation. This attempt proved 
unsuccessful, unfortunately, with the resulting sample being a single spot on TLC which could not 




Unfortunately, the acetylation reaction was carried out before 2D NMR spectroscopic experiments 
had been done on CV3, and time constraints did not allow for the re-isolation of the compound in 
order to acquire these spectra. Despite this, the data acquired should be sufficient evidence for the 
identity of CV3 as (6-epi)haemanthidine (24, 25).  
Only a portion of the available sample containing (6-epi)haemanthidine (24, 25) was used in the 
isolation and characterisation of the sample. Thus, the yield of this component was not acquired. 
However, recovery of impure CV3 from the remaining P1_10-12 (the mother-liquor of S1) was 
achieved by gravity column (C3.1), resulting in a fraction group containing CV3 as the major 
component. This impure CV3 sample had a mass of 658 mg. Because the sample was impure, it 
cannot be assumed that this was the mass of CV3 present in the filtrate of P1_10-12. However, given 
that CV3 was the major component of the sample (based on TLC analysis, and selective 
recombination of fractions containing CV3), it can be assumed that the mass of CV3 in the sample 
was relatively high. With the addition of the 133.1 mg of CV3 present in S1, it seems that C. variabile 
produces (6-epi)haemanthidine (24, 25) in relatively high concentrations. Unfortunately, despite the 
high concentration, time constraints did not allow for the exhaustive recovery of the alkaloid.  
8.2.2.6 Isolation of bulbispermine 26 
Following the characterisation of the major components in the first 12 fractions from P1 (P1_1-12), 
the rest of the fractions (P1_13-26) were considered. Based on TLC analysis of these fractions, it was 
decided that there was little opportunity for the selection of further fraction groups, so all these 
fractions were combined, and a silica column (C4) was used for the fractionation of the resulting 
sample. Given the relatively high polarity of the components in the sample, a DCM/MeOH gradient 
was selected as an elution strategy. This column resulted in approximately 650 fractions, which were 
grouped by TLC profile into 23 fraction groups (C4_1-23).  
Of these, C4_12-16 displayed TLC profiles containing components of interest, and were combined, 
as the spots present suggested that these components were present across the fraction groups. The 
resulting sample was dried under high vacuum and its mass was recorded at 211.2 mg. It was decided 
that a PLC plate (PP2) would be preferable as a means of separation for this sample, as this technique 
had provided more reliable separation of polar compounds than silica columns during previous 
experiments. It must be noted that a sample of this mass required a PLC plate with a thicker stationary 
phase than those previously used, to avoid overloading the plate. Thus, the entirety of the sample was 
dissolved in a minimum amount of MeOH and streaked onto the baseline of a PLC plate with a 2 mm 




The plate was developed three times in solvent system A, resulting in 4 fairly resolved bands of 
interest (PP2_1-4) when viewed under UV light. These bands were all removed and washed off the 
silica. They were then analysed by TLC, to gain further insight regarding their compositions. PP2_1 
(53.2 mg) showed a spot corelating to that of lycorine 19, and so was placed aside in the interest of 
finding a compound that had not previously been isolated from the plant. PP2_2 (66.7 mg) showed 
promising results in this regard, displaying a spot with a Rf lower slightly lower than that of lycorine’s, 
with relatively few, and visually less intense, additional spots (suggesting a relatively pure sample). 
The sample was subjected to 1H NMR spectroscopic analysis, which showed the presence of 
impurities, and so further purification steps were taken before full characterisation.  
PP2_2 was loaded onto an additional PLC plate (PP3) for this purpose. The plate was developed in 
solvent system A, and the band of interest (PP3_3) was removed and washed to recover the compound 
(this band was by far the most intense when viewed under UV light, with the other bands showing a 
very low response. Of course, the rest of the compound in the separation was not discarded, but also 
recovered and kept as a separate sample, though no components of interest were identified in these). 
The resulting major component (45.5 mg) was subjected to NMR spectroscopic analysis and found 
to be bulbispermine 26 (Figure 8.2.8), as shown in Table 8.12 and Table 8.13.  
 
Figure 8.2.8 - Numbered chemical structure of bulbispermine 26. 
Table 8.12 - The proton chemical shifts for bulbispermine 26. Literature values are cited from Luchetti et al. (2012).90 
Proton δ (ppm) Lit. δ (ppm) Acquired 
H-1 6.04 d 6.03 br d, J=10.3 Hz 
H-2 6.23 dd 6.22 dd, J=10.3, 2.3 Hz 
H-3 4.36-4.29 m 4.31 m 
H-4α 2.15-2.03 m 2.10 m 
H-4β 1.98-1.91 m 1.96 m 
H-4a 3.44 dd 3.23 m 
H-6α 3.73 d 3.74 d, J=16.7 Hz 
H-6β 4.27 d 4.28 d, J=16.7 Hz 
H-7 6.52 s 6.51 s 
H-10 6.85 s 6.85 s 




H-12 endo 3.25-3.17 m 3.45 dd, J=13.8, 7.0 
H-12 exo 3.25-3.17 m 3.23 m 
O-CH2-O 5.87 s 5.87 dd, J=3.1, 1.1 Hz 
Solvent CD3OD CD3OD 
 
Table 8.13 - The carbon chemical shifts for bulbispermine 26. Literature values are cited from Luchetti et al. (2012).90 
Carbon δ (ppm) Lit. δ (ppm) Acquired Δδ 
1 136.7 137.18 0.48 
2 124.2 124.69 0.49 
3 68.0 68.26 0.26 
4 33.8 34.24 0.44 
4a 67.7 67.45 -0.25 
6 60.9 61.31 0.41 
6a 125.2 126.40 1.2 
7 104.4 107.80 3.4 
8 148.0 147.69 -0.31 
9 148.5 148.16 -0.34 
10 107.9 104.23 -3.67 
10a 137.4 137.23 -0.17 
10b 51.6 51.42 -0.18 
11 80.4 80.86 0.46 
12 63.3 63.58 0.28 
OCH2O 102.4 102.23 -0.17 
Solvent CD3OD CD3OD  
 
These assignments were verified with 2D NMR spectroscopic experiments, including HSQC, HMBC 
and COSY (please see Appendix A for spectra), as well as by comparison with literature data. The 
greatest differences from literature values (Δδ) noted for the 13C NMR peak shifts were those of C-7 
and C-10, though this is due to differing assignments, which will be explained below. Other 
inconsistencies which may be noted are the differing signs of the Δδ values, and the greater difference 
for C-6a. Though these are certainly significant factors, the only explanation which can be offered is 
the possibility of the presence of impurities in the NMR sample of 26. Similar such errors in the 
literature values may also contribute to these inconsistencies. Despite the differences noted, the 
identification of 26 as bulbispermine is maintained with reasonable confidence, given the body of 
evidence in favour of this identity.  
It may be noted that in comparing the 1H spectra, assignments for H-4a and H-12 endo are switched 




assignments can be found in the HSQC spectrum, in which the peaks at 3.45 and 3.23 ppm both 
couple to the same carbon atom (that assigned as C-12), while the peak at 3.23 ppm also couples to 
the carbon assigned as C-4a. Another two assignments which have been interchanged from those 
reported in the literature are those for C-7 and C-10 in the 13C NMR spectrum. The reason this was 
done was that the HSQC showed coupling between H-10 and the peak at 104.23 ppm in the 13C NMR 
spectrum, as well as coupling between H-7 and the peak at 107.8 ppm in the 13C spectrum. The reason 
H-10 and H-7 were not switched as assignments instead of their corresponding carbons was that the 
COSY spectrum showed stronger coupling between H-7 and H-6(α and β) than between H-10 and H-
6(α and β), which is consistent with the proposed structure. 
11-hydroxyvittatine 31a (Figure 9.2.5) is a stereoisomer of bulbispermine 26, with inverted 
stereochemistry of the 3-hydroxy group. The possibility that 26 was 11-hydroxyvittatine was ruled 
out by comparison with the literature data, in which the acquired 1H NMR spectra were in better 
agreement with bulbispermine 26 than 11-hydroxyvittatine 31a.87,90 Optical rotation experiments for 
26 resulted in an [𝛼]𝐷
20 of +87.5° (c=1, MeOH), which also compared more favourably to 
bulbispermine (lit. [𝛼]𝐷
20 of +107°, c=1.02, MeOH91) than to 11-hydroxyvittatine 31a ( lit. [𝛼]𝐷
25 of 
+11.3°, c=0.88, MeOH92). The presence of some minor impurities, as well as possible human error 
in terms of correct concentration values, may account for the difference between acquired values and 
those from literature.  
Hamayne 31b (Figure 9.2.5) is another such stereoisomer with inverted stereochemistry of the 11-
hydroxy group. Unfortunately, this alkaloid does not have well-defined spectral data available in the 
literature, though the acquired [𝛼]𝐷
20 value still compares more favourably with bulbispermine 26 than 
with hamayne 31b (lit. [𝛼]𝐷
12 of +43°, c=0.1, EtOH93). 
MS analysis showed a peak for [M+H]+ at 288.1238, correlating to the expected molecular formula 
of C16H17NO4 (after removal of a proton to account for ESI +ve). The calculated mass for [M+H]
+ is 
288.1236, with a mass difference between calculated and acquired masses of 0.7 ppm. Please see 
Table 8.17 for fragmentation information.  
8.2.2.7 Isolation of criwelline 27                                                                                                                    
Having characterised the major component of PP2_2, attention was turned to the other bands from 
PP2. As has been established, four bands were removed from the plate, the first of which correlated 
with lycorine 19 when analysed with TLC, and the second of which was characterised as 
bulbispermine 26. Thus, the third and fourth bands (PP2_3-4) were then focused on, and it was 
decided based on TLC analysis that they should be recombined and subjected to further separation 




were of interest as they had not yet been isolated). Thus, the samples were recombined and subjected 
to further separation by PLC (this plate being labelled PP4).  
PP4 was developed three times in CHCl3:EtOAc:MeOH (2:2:1), resulting in three bands (PP4_1-3). 
When attempting to analyse these bands by TLC, difficulties were faced in lieu of the high polarity 
of the compounds. Defined profiles for the samples were difficult to achieve, as the components 
exhibited streaking on silica, making resolved spots impossible to achieve with conventional silica 
TLC plates. A few optimisation attempts were made in the hopes of solving this problem, including 
the use of alumina plates, as well as silica plates which had been pre-treated with triethylamine (NEt3). 
The reason plates treated with NEt3 were more likely to work is that the base could interact with the 
acidic sites on the silica, reducing the strong interactions with the alkaloid bases which were likely 
the cause of the streaking.  
The most promising results were obtained when PP4_1-3 were spotted on an alumina TLC plate and 
developed using 100% EtOAc. The result of this experiment was that a single spot moved up the 
plate, resolving itself from all the other components, which remained at the baseline. The component 
was present almost exclusively in PP4_2, with very light spots present in the other two bands. It was 
thus decided that PP4_2 would be subjected to further separation using a small column (the mass of 
the sample was only 19.1 mg, so large stationary phase quantities were avoided) with alumina as a 
stationary phase. The sample was dry loaded in its entirety onto alumina, and the column (C5) was 
eluted with 100% EtOAc. Fractions were monitored using alumina TLC analysis, and the fractions 
containing the spot of interest (which was the first to elute) were combined until signs of additional 
spots were observed.  
The sample showing only the spot of interest (C5_1) was dried under high vacuum, weighed (6.4 
mg), and subjected to NMR spectroscopic analysis. The resulting spectra were those of criwelline 27 
(Figure 8.2.9), as summarized in Table 8.14 and Table 8.15.  
 




Table 8.14 - The proton chemical shifts for criwelline 27. Literature values are cited from Bastida et al. (2006).87 
Proton δ (ppm) Lit. δ (ppm) Acquired 
H-1 5.78 d 5.79 d, J=10.1 Hz 
H-2 6.20 dd 6.20 dd, J=10.2, 3.6 Hz 
H-3 3.89 ddd 3.89 m 
H-4α 1.93 ddd 1.94 ddd, J=15.0, 6.0, 3.6 Hz 
H-4β 2.09 ddd 2.09 ddd, J=14.9, 4.4, 3.5 Hz 
H-4a 2.95 t 2.97 t, J=4.2 Hz 
H-6 4.68 d 4.67 d, J=14.7 Hz 
H-6ʹ 4.94 d 4.93 d, J=14.7 Hz 
H-7 6.55 s 6.53 s 
H-10 6.52 s 6.50 s 
H-12 2.83 d 2.86 d, J=10.4 Hz 
H-12ʹ 3.30 d 3.33 d, J=10.4 Hz 
O-CH2-O 5.92 s 5.90 dd, J=4.2, 1.3 Hz 
OMe 3.45 s 3.44 s 
NMe 2.38 s 2.41 s 
Solvent CDCl3 CDCl3 
 
Table 8.15 - The carbon chemical shifts for criwelline 27. Literature values are cited from Bastida et al. (2006).87  
Carbon δ (ppm) Lit. δ (ppm) Acquired Δδ 
1 130.1 130.29 0.19 
2 128.9 129.08 0.18 
3 72.1 72.20 0.1 
4 25.4 25.62 0.22 
4a 68.2 68.60 0.4 
6 62.6 62.75 0.15 
6a 126.2 126.43 0.23 
7 108.5 108.68 0.18 
8 146.6 146.82 0.22 
9 146.2 146.49 0.29 
10 104.2 104.37 0.17 
10a 130.9 131.66 0.76 
10b 50.0 50.25 0.25 
11 102.6 102.71 0.11 
12 64.5 64.61 0.11 
OCH2O 100.9 101.10 0.2 
OMe 56.7 56.90 0.2 




Solvent CDCl3 CDCl3  
 
These assignments were verified using 2D NMR spectroscopic experiments including HMBC, HSQC 
and COSY (please see Appendix A for spectra), as well as by comparison with literature data. 
Regarding the Δδ values presented in Table 8.15 above, the acquired 13C NMR peak shifts are in 
relatively good agreement with those reported in the literature. The values all share the same sign, 
indicating a constant shift in one direction (deshielded). One possible outlying value is that for C-
10a, though this may be explained by the presence of some impurities in the NMR sample of 27, for 
which there is evidence in the 1H NMR spectrum.  
MS analysis showed a [M+H]+ peak at 332.1499, correlating to the expected molecular formula of 
C18H21NO5 (after removal of a proton to account for ESI +ve), which adds credence to the 
identification as criwelline 27. The calculated mass for [M+H]+ of this formula is 332. 1498, with a 
difference between calculated and acquired masses of only 0.3 ppm. Please see Table 8.17 for 
fragmentation information. Optical rotation experiments provided an [𝛼]𝐷
20 of +163.1, c=0.325, 
CHCl3 (lit. [𝛼]𝐷
20 of +278°, c=0.213, CHCl3
94). 
It was verified that compound 27 was criwelline and not tazettine 36 (Figure 9.2.10) (a stereoisomer 
with inverted stereochemistry of the 3-methoxy group) by comparison of 1H NMR spectra. The 1H 
NMR spectrum of tazettine did not correlate with the acquired spectrum87,95, while that of criwelline 
27 did.87    
8.2.3 HPLC-ESI-MS/MS analysis of CVAlk.EXT 
Time constraints meant that the remaining fractions could not be investigated further, though there 
were undoubtedly alkaloidal constituents remaining in some of the fractions (such as the more polar 
fractions from C4, and the rest of the components from PP4). In an attempt to gain some information 
to assist in the tentative identification of the remaining alkaloidal constituents, a small amount of the 
original alkaloidal extract was analysed using HPLC-MS/MS. This resulted in a TIC (Figure 8.2.10) 





Figure 8.2.10 - TIC of HPLC-ESI-HRMS analysis of CVAlk.EXT. 
Table 8.16 - Table showing the HRMS and fragmentation (MS/MS) data for the peaks in the TIC of CVAlk.EXT.  
Retention 
Time/min 




Fragments (m/z) Possible Identity 
0.82 C16H17NO4 (1.4) 
288.1232 
(288.1236) 
270, 252, 222, 177, 147, 
119, 91 
Lycorine 1996 
1.03 C16H17NO4 (1.7) 
288.1231 
(288.1236) 
266, 226, 199, 184, 147, 
123, 119 
Unidentified 
1.14 C16H17NO4 (1.4) 
288.1232 
(288.1236) 
270, 252, 222, 177, 147, 
119, 91 
Lycorine 1996 
1.50 C16H17NO5 (1.3) 
304.1181 
(304.1185) 
286, 268, 250, 226 
11-hydroxyvittatine-N-
oxide 2997 
1.72 C18H21NO5 (3.6) 
332.1486 
(332.1498) 
211, 183, 140 Unidentified 
1.87 C16H17NO4 (1.7) 
288.1232 
(288.1236) 
270, 244, 226, 224, 211, 
196, 181, 153, 141, 115 
Bulbispermine 26 
2.15 C18H19NO5 (0.0) 
330.1341 
(330.1341) 
270, 252, 222, 194, 177, 







300, 286, 268, 250, 240, 
227, 224, 211, 209, 199, 
192, 181, 169, 165, 153, 
141, 115 









2.47 C18H19NO6 (0.6) 
346.1288 
(346.1291) 







2.52 C18H19NO5 (0.9) 
330.1344 
(330.1341) 
270, 266, 252, 227, 226, 




2.65 C18H19NO4 (1.0) 
314.1395 
(314.1392) 




2.77 C20H21NO6 (0.8) 
372.1450 
(372.1447) 
270, 252, 222, 194 
1,2-O,O-
diacetyllycorine 21 
2.97 C18H21NO5 (1.2) 
332.1494 
(332.1498) 
300, 268, 250, 227, 199, 
197, 169, 141, 115 
Unidentified 
3.34 C22H17NO3 (1.2) 
344.1291 
(344.1287) 
224, 166, 121, 103 
Unidentified – structural 
similarities are noted 
4.11 C22H17NO2 (0.9) 
328.1335 
(328.1338) 
367 (K adduct), 224, 
166, 144, 105 
4.58 C15H13NO2 (2.9) 
240.1032 
(240.1025) 
224, 210, 182,167, 166, 
139 
*The difference in calculated mass and that obtained for the molecular ion. **The calculated mass for [M+H]+. Numbers in bold 
represent base peak ions in cases where this is not the molecular ion. 
Table 6.16 (below) can be used as a means of comparison when identifying the peaks presented above.  
The peak at 1.03 min could not be conclusively identified, though Amaryllidaceae alkaloids matching 
its molecular formula were researched. Pluviine was ruled out as a possibility, given that its ESI+ve 
fragmentation pattern did not match that of the peak.101 Other possible compounds include 
nangustine, obesine and pancracine, though their ESI+ve fragmentation patterns were unavailable for 
comparison. 
The peak at 1.50 min corresponds well with the ESI-MS/MS information of 11-hydroxyvittatine-N-
oxide 29 (Figure 9.2.3)97, showing good correlation with the fragments reported in the literature. An 
interesting possibility to consider would be that this compound may be an N-oxide of bulbispermine 
26, rather than one of 11-hydroxyvittatine 31a (Figure 9.2.5), given the presence of 26 in the extract. 
However, no literature reports on bulbispermine-N-oxide are available, and so there is no evidence 
available to support this notion. 
The peak at 1.72 min with a molecular formula of C18H21NO5 could not be identified. This molecular 
formula is shared by many Amaryllidaceae alkaloids, though of those with reported ESI+ve MS 
fragmentation patterns, none were consistent with the fragments observed for this peak. 
The peak at 2.15 min on the TIC is most likely that of 1-O-acetyllycorine 23. The reasoning for this 
is as follows: the MS spectra of 1-O-acetyllycorine 23 and 2-O-acetyllycorine 22 differ in that 2-O-
acetyllycorine 22 does not produce mass fragments at 177 and 134 m/z, and the fragment at 147 m/z 
produces a more intense peak than that from 1-O-acetyllycorine 23 (please see Table 8.17). The mass 




O-acetyllycorine 23 well, showing peaks at 177 and 134 m/z, and a less intense 147 m/z peak than 
that from 2-O-acetyllycorine 22. 
Interestingly, it seems as though 2-O-acetyllycorine 22 co-eluted with 1-O-acetyllycorine 23, though 
22 eluted very slightly later, generating a peak for both compounds, which contained more of 22 at a 
later retention time and more of 23 at an earlier retention time. The reason this is suggested is that 
during the data analysis of this peak, the fragmentation spectrum of the later edge of the peak was 
subtracted from that of the earlier edge (a function which is possible using Masslynx® software). The 
result was a mass spectrum containing only a single fragment of m/z 134, which is a fragment present 
in 1-O-acetyllycorine 23, but not in 2-O-acetyllycorine 22. This information supports the postulation 
that 22 is present in the later edge and not the early edge. Additionally, a peak corresponding to 2-O-
acetyllycorine 22 was not present anywhere else on the TIC.  
Eluting under the peak for (6-epi)haemanthidine (24, 25) at 2.24 min, was a peak with an [M+H]+ 
mass of 332. This was identified as criweline 27, as there were no other peaks matching the molecular 
formula and fragmentation pattern of 27 in the TIC (the peaks at 1.72 and 2.97 min did not have 
analogous fragmentation patterns). Unfortunately, the fragments could not be identified, as those of 
(6-epi)haemanthidine 24, 25 were far more intense, and thus overshadowed those of the smaller peak 
of m/z 332.  
The peak eluting at 2.47 min with a molecular formula of C18H19NO6 corresponded to few 
Amaryllidaceae alkaloids reported in the literature. Only candimine98 and tazettamide99 were 
consistent with this molecular formula, based on literature searches. The fragment at m/z 316 
represented the loss of CH2O from the [M+H]
+ ion. This suggests the presence of a methylenedioxy- 
group, though this is consistent with both structures. The major peak in the fragmentation spectrum 
was that at m/z 226, This fragment is consistent with the loss of  120 mass units, corresponding to the 
loss of three fragments, those being MeOH (from a methoxy substituent), CH2O (from a 
methylenedioxy substituent), and CH3NCOH. The third of these is present as a substituent on 
tazettamide,99 making it the more likely candidate.  
The peak at 2.52 min had a molecular formula of C18H19NO5 and showed many peaks in common 
with bulbispermine 26, which indicated a similar structure to 26, though with one acetylated hydroxy 
group. The peak shared several mass fragments with those reported for 3-O-acetylhamayne (yeminine 
A),100,102 which is an acetylated analogue of hamayne 31b, a stereoisomer of bulbispermine 26. 
However, several mass fragments of the unknown compound were not present in the reported mass 
spectrum of 3-O-acetylhamayne.100 The fragmentation pattern of the unknown compound was in 




peaks (m/z 196, 168) which were not reported for the aforementioned isomer.100 Given the presence 
of bulbispermine 26 in the extract, it was suspected that the unknown compound was the 3-O-acetyl- 
analogue thereof (theoretically 3-O-acetyl-bulbispermine).  
The peak eluting at 2.65 min with a molecular formula of C18H19NO4 corresponded to three 
compounds in the literature, namely 3-O-acetylvittatine, 3-O-acetylcrinine and 1-O-acetylcaranine. 
3-O-acetylvittatine and 3-O-acetylcrinine were more likely, sharing structural skeletons with 
bulbispermine 26. Fragmentation patterns for these compounds using electrospray ionisation were 
unavailable, and so this unknown compound could not be confidently identified. However, some 
fragments were shared with the EI-MS/MS fragments of 3-O-acetylvittatine103, adding further 
credence to the possibility that this was the identity of the unknown compound. An interesting 
consideration would be the possibility that this unknown is the theoretical 3-O-acetyl-epivittatine 
(simply inverted stereochemistry of the 3-acetyl group of 3-O-acetylvittatine). The stereochemistry 
of 3-O-acetyl-epivittatine would correspond more favourably with that of bulbispermine 26, which 
has been shown to be present. However, 3-O-acetyl-epivittatine has not been previously reported in 
the literature, and so there is no evidence available to support this notion. 
The peak eluting at 2.97 min with a molecular formula of C18H21NO5 could not be matched with any 
compounds for which the ESI-MS fragmentation information has been reported. However, the 
presence of fragments at m/z 300 and 268 suggest the losses of MeOH and 2×MeOH respectively, 
which may indicate the presence of two methoxy groups. The peak at 250 may represent the loss of 
water thereafter, which could be an indication of a hydroxy group as well.  
The peaks eluting at 3.34, 4.11 and 4.58 had unusual molecular formulae and fragmentation patterns, 
and could not be matched to any known Amaryllidaceae alkaloids. The compounds in these peaks 
appeared to be structurally similar, all producing abundant fragments at m/z 224 and 166, which are 
rarely observed for ESI-MS/MS analyses of Amaryllidaceae alkaloids.96,97,100,101,104,105 These results 
may indicate the presence of novel alkaloids, which could be of interest for future investigations. 
The presence of two peaks corresponding perfectly in both molecular formula and fragmentation 
pattern with lycorine was noted. A possible reason for this observation is the conversion of an 
acetylated lycorine analogue into lycorine during the separation. The HPLC analysis was carried out 
using a mobile phase containing formic acid, and the acidic conditions on the column may have 
resulted in the hydrolysis of an acetate of lycorine. This may also be an alternative explanation for 




Table 8.17 - The HRMS data for all isolated compounds from C. variabile.  





1 Lycorine 19 C16H17NO4 (1.7) 
288.1241 
(288.1236) 
270, 252, 177, 147, 119, 91 
2 1,2-O,O-diacetyllycorine 21 C20H21NO6 (0.0) 
372.1447 
(372.1447) 
270, 252, 222, 194 
3 2-O-acetyllycorine 22 C18H19NO5 (1.5) 
330.1346 
(330.1341) 
270, 252, 222, 194, 147, 119 
4 1-O-acetyllycorine 23 C18H19NO5 (1.5) 
330.1346 
(330.1341) 
270, 252, 222, 194, 177, 147, 
134, 119 
5 





300, 286, 268, 250, 240, 227, 
224, 211, 209, 199, 192, 181, 
169, 165, 153, 141, 115 
6 Bulbispermine 26 C16H17NO4 (0.7) 
288.1238 
(288.1236) 
270, 244, 226, 224, 211, 196, 
181, 153, 141, 115 
7 Criwelline 27 C18H21NO5 (0.3) 
332.1499 
(332.1498) 
314, 230 202, 181, 159, 153 
 
8.3 General comments pertaining to the above processes 
During the process of isolating components from CVAlk_EXT, the order of isolations was guided 
by the Rf of components on silica TLC. Essentially, the component represented by a spot at the top 
of the TLC profile was isolated first, followed by the spot directly below that, and so on and so forth.   
As will have been noted in the introduction to this chapter, C. variabile has been the subject of only 
one phytochemical study prior to this project.74 During the investigation, the presence of 
galanthamine (20) in C. variabile was verified. Despite this finding, it must be noted that 
galanthamine (20) was not isolated during this project. Tanahashi et al. (1990)74 determined a yield 
of 0.006% from dried bulbs, which is a relatively low concentration of the alkaloid (6 mg per 100g 
dried bulb). This value is, of course, not constant across all specimens of C. variabile, with alkaloidal 
constituents of a single plant being dependant on a range of factors such as climatic conditions, time 
of harvest, and several others. Thus, it cannot be expected that exactly the same concentration of 
galanthamine 20 (or even any at all) would be present in the plant material used in this project.  
The TIC acquired from LC-ESI-MS/MS analysis of CVAlkEXT showed no peaks containing the 
mass components expected for galanthamine. None of the peaks present in the TIC provided the 
molecular formula expected for galanthamine upon elemental composition analysis. The conclusion 
to be drawn from this is that galanthamine was not present in the specimen used for this project, 




When carrying out a gravity column or washing compounds off silica, solvent systems with methanol 
composition higher than around 20% were generally avoided. The reason for this is that a white 
residue was noted in fraction collection vessels when working with higher methanol content in mobile 
phases. Thus, to avoid samples containing this residue (which would affect the masses acquired, and 
thus the yields reported), methanol content was kept at 20% or below, as a general procedural 
guideline.  
Another precaution taken when working with PLC plates was exposure to air for long periods of time. 
Given that compounds bound to silica have high surface area, exposure to air increases the risk of 
oxidation. Thus, when plates were removed from the chamber after development, attempts were made 
to limit their exposure time to only as long as was required for drying. If further development runs 
were required, and could not be carried out immediately, plates were kept in a freezer at -18°C until 
they could be further processed.  
When washing compounds from silica scraped off PLC plates, filtration through a packed bed of 
celite was useful as a means of ensuring no silica was washed into the filtrate. The celite was pre-
washed with the solvents to be used, so as to ensure that no celite was washed into the filtrate.  
When it is stated that a 1H NMR spectrum showed impurities, the evidence for this in the spectrum 
was generally the presence of smaller peaks at unexpected shifts, with integrals that did not correlate. 
When an “impure” 1H NMR spectrum was acquired, the sample was purified further before 2D NMR 
experiments were carried out, as these experiments were time consuming and thus expensive.  
Observations such as “the sample showed a single spot under UV light and Dragendorff’s reagent” 
were not taken as proof of a pure sample, but were used as a fairly reliable indicator, since the 
Amaryllidaceae alkaloids are generally UV active, and Dragendorff’s reagent is selective for 
alkaloids. Of course, the presence of non-alkaloidal constituents which were unresponsive to UV was 
always a possibility when only a single spot was noted, but the extraction method minimised the risk 
in this regard. Thus, a sample showing a single spot under both UV and Dragendorff’s reagent could 
generally be taken as a tentative indicator that the sample contained an acceptably pure alkaloid. 
8.4 Conclusions and future work 
The isolation and complete characterisation of compounds 19, 21, 22, 23, 24&25, 26 and 27 was 
successfully achieved. Unfortunately, all of these compounds have been previously reported, though 
lycorine 19 was present in remarkably high concentrations in the bulbs of C. variabile. This could 
prove useful as a production method for lycorine 19, which is of high interest for its multi-faceted 




Of course, the exhaustive investigation of the compounds in a plant species is a tremendous task, and 
this investigation did not result in the isolation of even all the alkaloidal constituents (as can be seen 
by the HPLC-ESI-MS analysis of the extract). Thus, a task of interest for future research could be the 
isolation of those compounds which could not be isolated or identified in this extract of C. variabile 
bulbs. Use of HPLC-ESI-MS could prove very effective in identifying fractions containing previously 
unknown compounds. The data acquired during this project could prove to be valuable for comparison 
during such investigations. 
Time constraints did not allow for the in-depth investigation of all the samples acquired during the 
separation steps of this project. Some fractions which may have been of interest for further 
investigation are as follows: C1_1-7 (though these fractions would contain relatively non-polar 
compounds, and did not show much promise upon TLC analysis); the remaining C2 fractions, C2_1,2 
and 4 (these were not investigated as there were no obvious targets for isolation, though further 
investigation may reveal small quantities of additional alkaloids); C3.1 fractions (these fractions 
contained a large portion of P1_10-12, and though CV3 was the main target during this project, TLC 
analysis provided evidence of other components); C4_1-11 and 17-23 (these fractions contained some 
of the more polar components of the extract, and despite the challenges faced while working with 
such samples, there are likely alkaloids present which this project did not reveal). 
Separation of the epimers of haemanthidine (24 and 25) could be achieved by generating analogues 
which are more easily separated. A semi-synthetic investigation of this nature may reveal a simple 
method of separation that could prove useful in this regard. 
Acquisition of a haemanthidine 24 standard would allow for the comparison of MS fragments with 
those of CV3, allowing for more conclusive results. Further investigations concerning the 
fragmentation pattern acquired for CV3 may reveal fragmentation mechanisms which better explain 
the observed peaks.  
Previous studies have shown that the alkaloidal composition of the bulbs of a plant is not the same as 
those of the leaves and roots.106 Thus, perhaps investigation of the other parts of this plant species 





9      Crinum paludosum 
9.1 Introduction 
Crinum paludosum produces white (sometimes light to deep pink) bell-shaped flowers and was first 
described fairly recently in 1968. It was illustrated using a specimen grown in Limpopo, from a plant 
originally found in Zululand.53 The species name paludosum refers to the marshy habitat in which the 
species naturally occurs. It is found widely throughout 
southern Africa, with known areas of distribution in 
northern KwaZulu-Natal and Zululand, Gauteng, central 
Namibia, Botswana, eastern Zimbabwe and western 
Mozambique. C. paludosum is associated with seasonally 
flooded pans, marshes, etc., with clay soil that dries to be 
hard in the dry season. Due to the sparse and intermittent 
rainfall in some of these areas, it has evolved to become 
completely dormant in the dry season, sometimes 
remaining so for over a decade until favourable 
conditions are established.53 Cultivation methods have 
been established, though susceptibility to fungal rot and 
invasive caterpillars makes it somewhat challenging.53  
To the best of our knowledge, there have been no 
investigations focused on the alkaloidal constituents of C. 
paludosum. Thus, this investigation will add some value 
to the field. The aim of the investigation carried out on this species was not the isolation of novel 
actives, but a time-efficient analysis of the alkaloidal constituents. It was also of interest, however, to 
determine the concentration of lycorine 19 in the dry bulbs of the species, given the relatively high 
concentration obtained from C. variabile, as discussed in the previous chapter.  
 
Figure 9.1.1 – A botanical illustration of Crinum 
paludosum, drawn by Barbara Jeppe, taken from “The 
Amaryllidaceae of Southern Africa” by Graham 




9.2 Processing, results and discussion 
9.2.1 Preparation and extraction 
As with C. variabile, the bulbs of C. paludosum were obtained from a local nursery, and living 
specimens are present in the Botanical Gardens at the University of Stellenbosch (33°56'09.3"S 
18°51'56.9"E) as reference material. These specimens will be maintained, and dried voucher 
specimens will be prepared from them in the case of their demise. The bulbs were sliced, dried in air 
until constant mass was achieved, and stored in a freezer (−18°C) before further processing. The 
resulting dried slices were crushed under liquid nitrogen to maximise the surface area for extraction.  
The extraction of the C. paludosum bulb material began with acidic aqueous extraction of the 
prepared bulb material. 100 g of the material was submerged under 300 mL of 1% H2SO4 in H2O. 
This was stirred for 2 hours (pH remained acidic, as tested using litmus paper), after which the 
material was strained and extracted once again in the same manner. A total of three extractions were 
carried out in this way, and the aqueous portions were combined. The reasoning behind this was that 
the acid present would protonate alkaloidal species, generating their sulphate salt forms, which would 
be more soluble in water, given their ionic nature.  
Following this, the total aqueous extract was basified (checked using litmus paper) with NaOH. 
Theoretically, this will have generated the free-base forms of the alkaloids present, so that they could 
be extracted from the aqueous layer using an organic solvent. It may be noted that extraction of the 
acidic aqueous extract was not carried out before basification, as was done with C. variabile. This 
step was omitted in the interest of preserving any alkaloidal constituents which may move into the 
organic layer despite the acidic nature of the aqueous medium. Admittedly, the omission of this step 
somewhat decreases the selectivity of the extraction. However, despite this, all alkaloidal constituents 
would still be present in the extract, and the efficacy of the process remained robust.  
Following basification, the aqueous solution was extracted with 250 mL of EtOAc. This was done 
three times using a separatory funnel, and the EtOAc extracts were dried using MgSO4 and combined 
to obtain an alkaloidal extract (CPAlk.EXT, 0.4874 g after drying under high vacuum). In order to 
evaluate whether three EtOAc extractions was sufficient for the removal of the alkaloidal 
constituents, a continuous liquid/liquid extraction with EtOAc was then carried out on the aqueous 
layer (please see Appendix A for continuous liquid/liquid extraction apparatus). After 24 hours, an 
EtOAc extract was obtained which, after drying, had a mass of 0.2064 g. This mass is significant, 
suggesting that continuous liquid/liquid extraction is considerably more efficient than three 




9.2.1.1 Isolation of lycorine 19 
TLC analysis of CPAlk.EXT and the continuous liquid/liquid extract showed analogous alkaloidal 
profiles, verifying the assumption that continuous extraction yielded more of the alkaloidal extract of 
interest. Thus, both samples could be considered CPAlk.EXT aliquots. Of these aliquots, the one of 
mass 0.4874 g was used for the isolation of lycorine, as was done with CVAlk.EXT in the previous 
chapter. After the addition of methanol to the sample, a light-coloured solid did not dissolve. This 
was filtered off and washed with cold MeOH to yield 112.5 mg of pure lycorine 19 (spectra were 
identical to those shown in Appendix A for lycorine 19). 
The total mass of lycorine 19 in CPAlk.EXT can be calculated using the total mass of CPAlk.EXT 
(0.6938 g): total mass of lycorine 19 = 0.1125 ×
0.6938
0.4874
= 0.1601 g, which is 160.1 mg. This mass 
is equivalent to a yield of 0.16% of the mass of dry bulbs used. This yield was not as high as that 
noted from C. variabile, although this is not surprising, given the notably high concentration of 
lycorine 19 present in the dried bulbs of C. variabile.  
9.2.2 A brief LC-ESI-MS/MS dereplication study 
Having isolated lycorine 19 in the interest of obtaining its yield from C. paludosum, a brief 
dereplication study was carried out by HPLC-ESI-HRMS analysis of a small amount of CPAlk.EXT. 
The sample was subjected to separation by HPLC under identical conditions to those used for 
CVAlk.EXT, to allow for comparison of elution times with the identified alkaloidal components of 
C. variabile. MS analysis was also carried out using identical parameters for trustworthy comparison 
of fragmentation patterns. Below is shown the TIC acquired for this analysis (Figure 9.2.1). 
 




The table below (Table 9.1) contains the fragmentation patterns (as well as other information) that 
could be acquired for the peaks shown in Figure 9.2.1. 
 






[M+H]+ (m/z) (calc.)** Fragments (m/z) Possible Identity 
0.81 C16H17NO4 (2.4) 288.1229 (288.1236) 
270, 226, 177, 147, 
119, 91 
Lycorine 19 
1.00 C16H19NO5 (2.6) 306.1333 (306.1341) 
290, 284, 266, 228, 
213, 136 
Unidentified 
1.12 C16H17NO4 (0.7) 288.1234 (288.1236) 
270, 226, 177, 147, 
119, 91 
Lycorine 19 




C16H17NO5 (2.0) 304.1179 (304.1185) 




C16H17NO4 (0.3) 288.1235 (288.1236) 
270, 244, 226, 196, 
168 
11-hydroxyvittatine 31a, 
hamayne 31b, bulbispermine 
26 
2.14 C16H17NO4 (1.0) 288.1233 (288.1236) 
270, 242, 224, 199, 
185, 166, 153, 141, 
129 
Unidentified 
2.19 C16H17NO3 (0.4) 272.1288 (272.1287) 
254, 226, 196, 168, 
149, 136 
Vittatine 3296  
2.31 
C17H19NO5 (0.6) 318.1343 (318.1341) 
Overlapping peaks: 
286, 274, 268, 238, 
227, 226, 211, 209, 
199, 197, 181, 169, 
152, 141, 121 
Crinamidine 3397 
C18H21NO5 (0.9) 332.1501 (332.1498) Unidentified 
2.44 C17H19NO5 (0.6) 318.1339 (318.13410 
300, 268, 256, 230, 
224, 211, 202, 181, 
159, 153, 152 
(iso)tazettinol (34a, 34b)54 
2.51 C16H12NO3+ (1.5) 266.0813 (266.0817) 
236, 208, 178, 179, 
180 
Ungeremine 3596 
2.60                                                                                                                                                                               C18H19NO6 (2.9) 346.1301 (346.1291) 288, 224, 197, 169 Unidentified
2.77 C18H21NO5 (0.0) 332.1498 (332.1498) 
314, 300, 282, 256, 
238, 224, 230, 211, 
202, 181, 159, 153 
Tazettine 36 (comparison with 





3.59 C17H17NO3 (2.1) 284.1281 (284.1287) 147, 121, 119 
3,4-anhydropowelline 3771 
(low certainty) 
3.73 C18H19NO4 (2.5) 314.1384 (314.1392) 
336 (Na adduct), 
177, 145, 117 
Unidentified 
4.14 C18H19NO6 (0.3) 346.1292 (346.1291) 
368, 328, 271, 241, 
239, 211, 181, 153 
(+)-3α-hydroxy-6β-
acetylbulbispermine 38a104 
4.58 C15H14NO2 (0.4) 240.1026 (240.1025) 
224, 210, 182, 167, 
139 
Unidentified 
5.00 C14H10O2 (0.9) 211.0761 (211.0759) 181, 153, 152 NON-ALKALOIDAL 
*The difference in calculated mass and that obtained for the molecular ion. **The calculated mass for [M+H]+. Numbers in bold 
represent base peak ions in cases where this is not the molecular ion. 
The peak eluting at 1.00 min was not identified with much confidence, though the molecular formula 
and the presence of the fragment at m/z 290 corresponded to lycoramine-N-oxide 28 (Figure 9.2.2).96 
Some analogous peaks with the EI-MS/MS spectrum of lycoramine-N-oxide 28 were also noted,108 
suggesting structural similarity. 
 
Figure 9.2.2 - The chemical structure of lycoramine-N-oxide 28. 
The peak at 1.47 min corresponds well with the known ESI-MS/MS information of 11-
hydroxyvittatine-N-oxide 29 (Figure 9.2.3),97 showing good correlation with the fragments and 
molecular formula reported in the literature. The elution time of this compound is also in agreement 
with that of a similarly identified peak in CVAlk.EXT (Table 8.16). 
 
Figure 9.2.3 - Chemical structure of 11-hydroxyvittatine-N-oxide 29. 
At 1.89 min, a peak eluted which contained two compounds. One of these, with molecular formula 
C16H17NO5, showed good correlation to analogous EI-MS fragments reported for 2-epipancrassidine 
30a (Figure 9.2.4) by Ghosal et al. (1989).107 Of course, the possibility that this compound is 





Figure 9.2.4 - The chemical structures of 2-epipancrassidine 30a and pancrassidine 30b. 
The other peak at 1.89 min, with molecular formula C16H17NO4, corresponded somewhat with both 
the fragmentation pattern and the elution time of bulbispermine 26, as reported for CVAlk.EXT. 
However, some fragments observed for 26 were not seen for this peak, and the presence of a fragment 
at m/z 168 was not observed for 26 and were seen in the fragmentation pattern of this unknown. This 
suggests the possibility of an isomer, for which 11-hydroxyvittatine 31a and hamayne 31b (Figure 
9.2.5) are strong candidates. 
 
Figure 9.2.5 - The chemical structures of 11-hydroxyvittatine 31a, hamayne 31b and bulbispermine 26. 
The peak at 2.14 min with molecular formula C16H17NO4 could not be identified, as its fragmentation 
pattern was not consistent with any reported in the literature. Fragment peaks at m/z 224, 199, 166 
and 153 suggest structural similarities to (6-epi)haemanthidine (24, 25), which would indicate a 
haemanthamine-type alkaloid.  
The peak at 2.19 with molecular formula C16H17NO3
 showed good correlation with the reported ESI-
MS/MS fragments for vittatine 32.96 The molecular formula, as well as the evidence of the presence 
of 11-hydroxyvittatine 31a (peak @ 1.89 min), are further indications that this component was likely 
vittatine 32 (Figure 9.2.6). 
 




At elution time 2.31 min, there is a peak which shows the masses for two components. The component 
with molecular formula C17H19NO5 is most closely represented by crinamidine 33 (Figure 9.2.7), 
which has a correlating molecular formula, as well as matching fragments in its ESI-MS/MS 
spectrum.97 The component with molecular formula C18H21NO5 could not be matched with any 
alkaloids for which the ESI-MS/MS data was available in the literature. However, the component 
showed some analogous peaks to those of the EI-MS/MS fragments of tazettine 36 (Figure 9.2.10),109 
which may indicate a tazettine-type alkaloid. This may be an unknown alkaloid and may be of interest 
for further investigations. 
 
Figure 9.2.7 - The chemical structure of crinamidine 33. 
The peak at 2.44 min shows fragments remarkably similar to those of criwelline 27, though the 
molecular formula suggests that instead of the 3-methoxy group, this compound has a 3-hydroxy 
group. This corresponds to isotazettinol 34a (Figure 9.2.8).54 Of course, tazettinol 34b is also a strong 
candidate, especially given the identification of tazettine 36 in the extract (peak @ 2.77 min) 
 
Figure 9.2.8 - The chemical structures of isotazettinol 34a and tazettinol 34b. 
Though perhaps not clearly visible in the TIC above (Figure 9.2.1), a component eluted at 2.51 min 
which had a molecular formula of C16H12NO3
+. The fragmentation pattern of this component 
correlated with good agreement to that of ungeremine 35 (Figure 9.2.9) (This alkaloid appears to be 
stable in an ionic form, and so the removal of a proton was not necessary when considering its 





Figure 9.2.9 - The chemical structure of ungeremine 35. 
The peak eluting at 2.60 min had a molecular formula of C18H19NO6, which is consistent with some 
Amaryllidaceae alkaloids, such as candimine and tazettamide. However, the mass fragments 
produced by this peak could not be correlated to any such compounds in the literature. Thus, the 
compound remained unidentified. This could therefore be an unknown alkaloid, and further 
investigation may be of interest for future research. 
The peak at 2.77 min shared almost all of its mass fragments with the peak eluting at 2.44 min, and 
both showed base peaks at m/z 181. This suggests that these two compounds are likely structurally 
similar, though the molecular formula and the presence of a peak at m/z [M+H]+−32 (loss of MeOH) 
suggests the presence of a 3-methoxy group instead of a 3-hydroxy. Given the tentative identification 
of the peak at 2.44 min as (iso)tazettanol (34a, 34b), the peak at 2.77 min is likely tazettine 36. The 
fragmentation pattern of this peak contains all the fragments of criwelline 27 (and some additional 
peaks), but the difference in elution time from 27 suggests an isomer thereof, with which tazettine 36 
is consistent. Criwelline 27 is structurally very similar to tazettine 36, with only an inversion of the 
3-methoxy stereochemistry differentiating them. Thus, similar fragmentation patterns would not be 
surprising. 
 
Figure 9.2.10 - The chemical structure of tazettine 36. 
The peak eluting at 3.59 min with molecular formula C17H17NO3 was tentatively assigned as 3,4-
anhydropowelline 37 (Figure 9.2.11) only because this was the only Amaryllidaceae alkaloid with a 
corresponding molecular formula in the literature.71 The presence of the structurally similar 




information for 3,4-anhydropowelline 37 was available for comparison, and so the assignment as 
such is somewhat superficial. 
 
Figure 9.2.11 - 3,4-anhydropowelline 37. 
The peak eluting at 3.73 min had a molecular formula of C18H19NO4. This molecular formula 
corresponded with O-acetylcaranine, and the presence of a peak at m/z 177 was shared with the 
fragmentation pattern of lycorine (O-acetylcaranine is a lycorine-type alkaloid). Though these 
observations may add some slight credence to the possibility that the peak was O-acetylcaranine, the 
fragmentation pattern showed no analogous peaks to those reported for the EI-MS fragmentation of 
O-acetylcaranine.110 Thus, no definitive assignment could be made for this compound. This 
compound may be an unknown alkaloid and could be of interest for further investigation. 
The peak eluting at 4.14 min contained a component which had the molecular formula C18H19NO6 
and showed a fragmentation pattern which corresponded well to the reported ESI-MS/MS fragments 
of (+)-3α-hydroxy-6β-acetylbulbispermine 38a (Figure 9.2.12).104 Given that there is evidence for 
the presence of 11-hydroxyvittatine 31a in the extract (peak @ 1.89 min), the corresponding isomer 
(theoretically 6β-acetyoxy-11-hydroxyvittatine 38b) should be considered as a possibility.  
 
Figure 9.2.12 - The chemical structures of (+)-3α-hydroxy-6β-acetylbulbispermine 38a and the theoretical 6β-acetoxy-11-
hydroxyvittatine 38b. 
The compound eluting at 4.58 min with a molecular formula of C15H14NO2 was not identified, but 
was identical in both retention time and molecular formula to a peak observed in CVAlk.EXT.  
The presence of a non-alkaloidal constituent (peak @ 5.00 min) can likely be explained by the 
extraction process described at the beginning of this chapter. The omission of an organic extraction 




resulting in the presence of some non-alkaloidal compounds in the extract. Little can be said regarding 
the structure of this compound, as the trends seen in the structures of Amaryllidaceae alkaloids cannot 
be used as guidelines for non-alkaloidal constituents.  
Finally, the presence of two peaks corresponding to the molecular formula and fragmentation pattern 
of lycorine 19 was noted (peaks @ 0.81 and 1.12 min). As was suggested in the discussion of the 
HPLC-ESI-MS/MS analysis of CVAlkEXT, this may be due to the conversion of a lycorine 19 
derivative into 19 itself while on the column. The presence of formic acid in the mobile phase may 
have resulted in the hydrolysis of an acetyl group, thus generating lycorine 19 from a closely related 
compound, which could have then eluted at a different time to the lycorine 19 which was originally 
present in the sample (due to the time taken for this conversion to occur. It must be noted that this 
explanation is tentative, and further investigation would be required to confidently explain this result.  
9.3 Conclusions and future work 
The isolation of lycorine 19 was carried out, resulting in a yield of 0.16% from the mass of dried 
bulbs used. The data acquired from the LC-ESI-MS/MS analysis of the alkaloidal extract of C. 
paludosum (CPAlk.EXT) was used in a brief dereplication study to gain some insight regarding the 
alkaloidal constituents of the species.  
This research allowed for the tentative or partial identification of eleven alkaloids present in C. 
plaudosum and offered some insight into structural aspects of four others. Five alkaloids could not be 
identified from previous reports in literature, and each of these has some promise as a possibly novel 
alkaloid. The pursuit of new compounds is beneficial to the field of medicinal chemistry, and so these 
unidentified compounds may be targets of interest for further research in this area.  
Important to note is that, despite the usefulness of the data obtained from mass spectrometric analysis, 
the technique is not capable of unambiguous structural elucidation. It must therefore be kept in mind 
that the assignments suggested during this study were tentative and cannot be reported with absolute 
confidence. Despite this, the information provided is certainly sufficient to allow reasonable 
assumptions to be made, and in some cases, even for a compound to be identified with a fair level of 
certainty. 
A clear possibility for future research endeavours would be the isolation of the alkaloids present in 
C. paludosum, in the interest of confirming or disproving the suggested identities noted in this 
chapter. Compounds which are previously undiscovered are of highest interest in this regard, and 
even those compounds for which an identity has been suggested may prove to be novel (since some 




In conclusion, C. paludosum shows some promise for the discovery of novel compounds (including 





10 A Brief synthetic study on higginsianins A and B  
10.1 Introduction 
In a study by Evidente and colleagues (2016),73 two natural products compounds were isolated from 
the fungus Colletotrichum higginsianum, and were named higginsianins A and B (39 and 40 
respectively, Figure 10.1.1). The compounds both exhibited considerable antiproliferative activity 
against the human glioma cancer cell line Hs683. Higginsianin A exhibited an IC50 value of 1 µM, 
and higginsianin B one of 2 µM (these being concentrations required to inhibit cell growth by 50% 
after 72 hours of incubation). The compounds also showed promising results against some other cell 
lines, including a melanoma line (B16F10).73 
 
Figure 10.1.1 - The chemical structures of higginsianin A 39 and higginsianin B 40. The atom numbers for higginsianin B reflect 
those of higginsiainin A.  
As was discussed in the background chapter, derivatisation of natural products has proven invaluable 
in the field of drug discovery. Despite the inherent activity of the natural products compounds 
isolated, drug-like properties (as well as activity) can be greatly improved by structural 
alteration.37,40,41  As reported by Newman and Cragg (2016), of all the new approved drugs from 1981 
to 2014, 21% were natural products derivatives.37 This highlights the importance of synthetic 
modifications to natural products compounds in the search for new drugs.  
Thus, as a synthetic accompaniment to the current natural products-focused project, it was decided 
that a brief study would be done in which a few test reactions could be attempted on these two 
compounds. The purpose of this study was the synthesis of some analogues of 39 and 40, with the 




Samples of these compounds were acquired from the research group of Antonio Evidente, University 
of Napoli, Italy. Reactions were generally carried out on a 20 mg scale, to ensure that the available 
starting material (ca. 250 mg of 39 and ca. 350 mg of 40) could be subjected to a reasonable number 
of reaction attempts.  
10.2 Reactions  
10.2.1 Higginsianin A 39 
As the first reaction for Higginsianin A, it was decided that an acetylation would be of interest, as the 
acetate could be of use as a starting material for other reactions. The acetate of Higginsianin A 39 had 
already been acquired, and so was not novel.73  
 
Figure 10.2.1 - The reaction scheme of Higginsianin A 39 acetylation. Pyridine was used as a solvent, and acetic anhydride was added 
in excess. 
The acetylation reaction was left to stir for 24 hours, after which complete conversion to the acetate 
was achieved, and the reaction was poured over ice to precipitate 39a in 82% yield (45 mg). The 
proton NMR spectrum (Appendix B) was confirmed by comparison to the same product in the study 
by Evidente and colleagues (2016).73 
Following this, it was decided that acetate 39a would be a good starting material for an attempted 
Diels-Alder reaction. The intention was for the action of the lower pyrone ring as a diene, with 
previous evidence of analogous reactions.111 Maleic anhydride (1.1 eq) was used as a dienophile, and 
the reaction solvent was benzene. Unfortunately, the reaction did not proceed, despite attempts to 
promote it, such as the addition of a Lewis acid (AlCl3), and the addition of more maleic anhydride. 
The starting material was then recovered by gravity column (ca. 75% recovery – some may have been 




Acetate 39a was also used as a starting material for an attempted epoxidation reaction using meta-
chloroperbenzoic acid (m-CPBA) and DCM as a solvent. The reaction did not proceed, and heating 
to 30°C for ca. 48 hours still resulted in recovery of the starting material (ca. 90% recovery – 
recovered by extraction).  
Following this, hydrogenation of the double bonds of higginsianin A 39 was attempted using 10% 
palladium on carbon under positive H2 pressure. The reaction was attempted using dry MeOH as the 
solvent, and a balloon of H2 gas to provide a positive pressure. Unfortunately, this reaction gave rise 
to a mixture of many products, and the small quantity of each did not allow for isolation and 
characterisation of any primary products.  
A bromination reaction was then attempted using 39, making use of N-bromosuccinimide (NBS) (1 
eq.) and a catalytic amount of azobisisobutyronitrile (AIBN – a radical initiator) in DCM. The 
reaction was carried out under allylic bromination conditions, and resulted in full conversion of the 
starting material into two closely eluting compounds after 6 hours. Initially, an attempt was made to 
separate these two compounds by preparative TLC. However, the TLC resulted in a mixture of many 
compounds, suggesting degradation of the products on the silica plate. The reaction was then 
repeated, and the benzoic acid side product (from the m-CPBA starting material) removed by washing 
with sodium bicarbonate solution. A 1H NMR spectrum was then acquired of the product mixture 
after drying of the organic layer. Another 1H NMR spectrum was acquired two days later, having left 
the tube at room temperature (RT), and exposed to ambient light. The second spectrum showed that 
the compounds had once more degraded. These results led to the assumption that the products were 
either thermo- or photo-sensitive.  
Thus, the reaction was repeated a third time, keeping tinfoil over the reaction vessel to avoid light 
exposure. The products were isolated by extraction once again, and the NMR spectroscopic sample 
prepared from the resulting dried organic layer was kept in the fridge, wrapped in tinfoil. 
Characterisation of the product mixture by 1H, 13C and 2D NMR spectroscopic experiments (HSQC, 






Figure 10.2.2 - Reaction scheme of NBS bromination of higginsianin A 39. 
The reasoning behind the identification of these products is as follows: Bromination does not occur 
at position 13, as the H-12 and H-13 peaks remain unaffected in the 1H NMR spectrum for the product 
mixture. In the resulting 1H NMR spectrum, the peak representing H-18 (3H) was split from a singlet 
in the starting material into two singlets in the product mixture. Bromination at the C-4 position of 
39 would result in deshielding of the protons on C-18 (electron withdrawing nature of bromine). Thus, 
the more downfield of the two H-18 singlets represented that for 39c. The relative integrals of these 
two singlets suggested that approximately 40% of the 39 had been brominated at the C-4 position, 
and 60% had been brominated at the C-2 position. Shifts of the H-19 peaks also suggested a mixture 
of two products, as the original two peaks were split into four. The relative integrals of these peaks 
suggested similar product ratios as those discussed above. 
Separation of 39b-d (brominated products) was not carried out, due to time constraints not allowing 
the navigation of the difficulties associated with separating sensitive compounds. Both products are, 






10.2.2 Higginsianin B 40 
As with higginsianin A 39, the first reaction carried out for this compound was an acetylation reaction. 
This reaction was carried out in reagent grade chloroform, with excess pyridine and acetic anhydride. 
The reaction was monitored by TLC analysis, and the reaction was stopped once all the starting 
material had been consumed. At this point, two product spots were visible, and were isolated by 
washing the organic layer with 1M HCl, followed by brine. After drying of the organic layer, the two 
products were separated on by PLC and isolated for NMR spectroscopic analysis. The two 
compounds acquired (40a, 49.3%, 29.5 mg and 40b, 35.2%, 19.3 mg) were subjected to 1H and 13C 
NMR spectroscopic and HRMS analyses (Appendix B), and were identified as 8,22-O,O-
diacetylhigginsianin B 40a and 22-O-acetylhigginsianin B 40b. The scheme below shows the 
resulting compounds (HRMS analysis supports the identification of the products as those shown).  
 
Figure 10.2.3 - Reaction scheme of the acetylation of Higginsianin B 40. 
Comparing the 1H NMR spectra of the starting material 40 and the products 40a and 40b (Figure 
10.2.4), a shift of proton 8 only occurs in the spectrum of the diacetylated product 40a. This suggests 
that acetylation occurs preferentially on the hydroxy of the lower ring. A shift of one of the protons 
at the 19- position occurs in the spectra of both products, further supporting this hypothesis. 
Additionally, the peaks corresponding to H-20 were also affected in both products (which adds 
credence to the notion that acetylation occurred at the 22-hydroxy in both products). Furthermore, the 
appearance of additional methyl peaks in the product spectra are further evidence of the formation of 
the suggested products. Neither of these acetates were synthesised in the original study by Evidente 





Figure 10.2.4 – Comparison of 1H proton spectra for 40, 40a, and 40b. 
Following this, an oxidation of higginsianin B 40 was attempted using pyridinium chlorochromate 
(PCC). A common problem faced when using PCC is that the by-products form “clumps”, which can 
trap solid reagents, reducing surface area and slowing the reaction, as well as making the workup 
challenging.112 In order to solve this, the PCC was ground with a small amount of silica before using 
it in the reaction. The resulting fine yellow powder dispersed effectively in the reaction solvent. The 
expected product was one in which the secondary alcohol of higginsianin B 40 was transformed to a 
ketone. Unfortunately, the result of this reaction was a mixture of compounds that could not be 
identified due to the small quantities present.  
An ozonolysis of higginsianin B 40 was also attempted, using MeOH and DCM as solvents, and an 
acetone/dry ice slurry to maintain a cold temperature (−78°C) during ozone saturation. Me2S (4 eq.) 
was used to reductively work up. The reaction mixture was kept under oxygen or ozone throughout 
the length of the reaction, and so following the reaction progress with TLC analysis was not possible. 
TLC analysis of the resulting product mixture revealed a complex mixture. Attempts were made to 
gain further insight using HRMS, but this provided no useful information, as only species of 




degradation. (m/z 335, 345, 361 were acquired as masses of resulting components, suggesting 
degradation to smaller compounds, as the mass of the starting material was 428.6 u).  
As with higginsianin A 39, a reductive hydrogenation using palladium on carbon (Pd/C – 10%) was 
attempted on higginsianin B 40. This reaction produced a promising TLC profile after reaction in dry 
MeOH for 72 hours. The reaction mixture was prepared as a crude NMR spectroscopy sample, which 
unfortunately degraded (supposedly due to the acidic nature of CDCl3) before separation or 
characterisation were attempted. Time constraints did not allow for the repetition of this reaction, but 
given that the reaction proceeded, producing what appeared to be two spots on TLC (Figure 10.2.5), 
this reaction is promising for future investigation.  
 
Figure 10.2.5 - TLC profile of reaction with 40 and Pd/C at 72 hours. 
The crude 1H NMR spectrum (Appendix B) of the hydrogenation product mixture shows large shifts 
of peaks for H-19 and H-13, which supports the reaction scheme shown in Figure 10.2.6, as 
hydrogenation of the double bonds at these positions would result in protection of these protons, 
causing upfield shifts into the aliphatic range. The presence of two spots on TLC suggests two 
products, and the appearance of a quartet at δ4.13 ppm in the 1H NMR spectrum of the product 
mixture suggests the possibility of hydrogenation of the double bond at C-23 on the lower ring (Figure 
10.2.6). This would indicate 40d as a product, in which case H-24 may produce the aforementioned 
quartet (deshielding by the adjacent electron withdrawing oxygen atom may be the reason for the 






Figure 10.2.6 - Reaction of higginsianin B 40 with Pd/C. 
Epoxidation of higginsianin B 40 using m-CPBA was then attempted in DCM. The reaction 
proceeded slowly, and solubility of the starting material in DCM was sparing. However, after 
approximately 50 hours of stirring at room temperature, all the solid material had dissolved, and full 
conversion to a single spot on TLC was noted after 72 hours. Crude 1H NMR spectroscopic analysis 
(Appendix B) showed shifts of protons at position 19, which would support the scheme shown below 
(Figure 10.2.7). No shift was observed for H-13, suggesting that epoxidation did not occur at this 
position. Unfortunately, time constraints (and other circumstances) did not allow for purification of 
the product and full characterisation, though this would be an obvious step for further investigations.  
 
Figure 10.2.7 - Reaction of higginsianin B 40 with m-CPBA. 
10.3 Conclusions and future work 
This study resulted in the generation of 22-O-acetylhigginsianin A 39a, though this analogue had 
been previously reported.73 Also produced was a mixture of bromination products of 39, though full 




epoxidation with m-CPBA, diels alder with maleic anhydride, and hydrogenation of double bonds 
with Pd/C. However, these reactions proved unsuccessful, either yielding starting material, or a 
mixture of products which could not be characterised.  
From Higginsianin B 40 was produced 8,22-O,O-diacetylhigginsianin B 40a and 22-O-
acetylhigginsianin B 40b, both novel analogues. Oxidation with PCC and ozonolysis of 40 were 
attempted, though these reactions were unsuccessful, producing mixtures of compounds which could 
not be characterised. Reductive hydrogenation of 40 using Pd/C produced promising results, though 
degradation of the product(s) in CDCl3 meant that full characterisation could not be achieved. Lastly, 
epoxidation of 40 using m-CPBA resulted in a single apparent product when analysed by TLC. Some 
structural aspects could be inferred by crude NMR spectroscopic analysis, though time constraints 
did not allow for full characterisation. Of course, full characterisation of all products making use of 
2D NMR spectroscopy should be carried out to complete these studies. 
This study was only preliminary, providing only a small number of analogues. Thus, development of 
a more extensive library of derivatives is a key objective for future work. Additionally, biological 
testing of the acquired derivatives is imperative, in the interest of developing SARs for higginsianins 
A and B (39 and 40), as well as for the discovery of novel active compounds.  
In conclusion, the work presented above provides some useful information for the investigation of 39 
and 40 as drug leads, as well as some novel compounds for biological testing. However, far more 
extensive research in this area is needed for more meaningful conclusions to be drawn, and for SARs 





11 Methods and materials 
All chemicals were purchased from Sigma Aldrich or Merck. All 1H, 13C and 2D nuclear magnetic 
resonance spectra were obtained using a 300 MHz (75.5 MHz for 13C), 400 MHz (100 MHz for 13C) 
or 600 MHz (150 MHz for 13C) Varian VNMRS using deuterated solvents. 
11.1 Crinum variabile 
Optical rotations were obtained on a Perkin Elmer 343 Polarimeter at 20 °C.  
All chromatographic columns were prepared with a cotton wool plug at the base to minimise elution 
of unwanted solids (though columns with glass frits were invariably used).  
All PLC plates were of dimensions 20×20 cm and bands were visualised under UV light (254 nm 
wavelength). When isolating the compounds present in bands, silica was crushed to allow for 
effective washing.  
Spots on TLC plates were visualised under UV light (254 nm wavelength), as well as using 
Dragendorff’s reagent (prepared according to standard procedure). TLC plates used during the elution 
of a column were analytical grade aluminium-backed (Merck, high performance analytical TLC, 5 
cm length, F254). TLC plates used for profiling of extracts and solvent system optimisation were glass-
backed (Merck, silica gel 60, 0.25 mm film thickness, 10 cm length, F254).  
11.1.1 Separation experiments 
11.1.1.1 P1 
CVAlk.EXT.F (2.469 g) was dissolved in MeOH and loaded onto coarse silica (Merck, silica gel 60, 
0.063-0.200 mm), and placed under high vacuum to dry. P1 was prepared in a glass column (42 mm 
internal diameter (i.d.)), with a cotton plug at the base, followed by silica gel (25 g) (Merck, silica gel 
60, 230-400 mesh). An additional layer of cotton wool was placed above this, followed by the dried 
and loaded CVAlk.EXT.F.  
P1 was then eluted , in 700 mL volumes, with: 100% hexane, 10% EtOAc in hexane (EtOAc/hex), 
20% EtOAc/hex, 30% EtOAc/hex, 40% EtOAc/hex, 50% EtOAc/hex, 60% EtOAc/hex, 70% 
EtOAc/hex, 80% EtOAc/hex, 90% EtOAc/hex, 100% EtOAc, 2.5% MeOH/EtOAc, 5% 
MeOH/EtOAc, 10% MeOH/EtOAc, 15% MeOH/EtOAc, 20% MeOH/EtOAc, 100%DCM, 2.5% 
MeOH/DCM, 10% MeOH/DCM, 20% MeOH/DCM, EtOAc:MeOH:H2O (78.2:20:1.8), 
EtOAc:MeOH:H2O (76.4:20:3.6), EtOAc:MeOH:H2O (74.6:20:5.4), EtOAc:MeOH:H2O 




Each of these eluents was collected as a single fraction of P1, resulting in 26 fractions (P1_1-26). 
TLC analysis of these fractions (Figure 8.2.2) was carried out using EtOAc:MeOH:H2O (85:10:5) on 
a glass-backed TLC plate (Merck, silica gel 60, 0.25 mm film thickness, 20×20 cm, F254). The plate 
was pre-dried in an 80°C oven. 
11.1.1.2 C1 
50 g silica (Merck, silica 60, 230-400 mesh) was equilibrated in 100% hexane and poured into a 20 
mm diameter glass column. P1_1-6 (348 mg) was loaded onto 1.4 g silica gel (Merck, silica 60, 230-
400 mesh), and dried under high vacuum before being added to the top of C1.  
C1 was then eluted with: 100% hexane (70 mL), 1% EtOAc/hex (250 mL), 5% EtOAc/hex (250 mL), 
10% EtOAc/hex (250 mL), 20% EtOAc/hex (250 mL), 30% EtOAc/hex (1250 mL), 50% EtOAc/hex 
(500 mL), 60% EtOAc/hex (250 mL), 70% EtOAc/hex (500 mL).  
The eluent was collected in 15 mL fractions, which were analysed by TLC during elution, based on 
which fractions were combined into ten groups (C1_1-10). Compound 21 (221 mg) was isolated 
during elution of 30% EtOAc in hexane, which is the reason for the increased elution volume using 
this solvent (only once all of the compound had eluted was the solvent composition altered further).  
11.1.1.3 C1.1 
50 g silica (Merck, silica 60, 230-400 mesh) was equilibrated in 100% DCM and poured into a 20 
mm diameter glass column. C1_9 (53.1 mg) was sonicated in DCM (ca. 10 mL) and wet loaded onto 
C1.1.  
C1.1 was eluted in 250 mL volumes with: 100% DCM, 1% MeOH/DCM, 2% MeOH/DCM, 3% 
MeOH/DCM, 4% MeOH/DCM, 5% MeOH/DCM.  
15 mL fractions were collected and grouped based on TLC profile into 5 groups (C1.1_1-5). 
Compound 22 (45.2 mg) was isolated as C1.1_3. 
11.1.1.4 C2 
45 g silica (Merck, silica 60, 230-400 mesh) was equilibrated in 100% EtOAc and poured into a 20 
mm diameter glass column. P1_7-9 (286.2 mg) was loaded onto 1.2 g silica (Merck, silica 60, 230-
400 mesh), and added to the top of C2.  
C2 was eluted using a single isocratic mobile phase of 100% EtOAc. 15 mL fraction were collected 
and, based on TLC analysis, were grouped into four fraction groups C2_1-4. The component of 





C2_3 (224 mg) was dissolved in MeOH and streaked onto the baseline of two PLC plates (Merck, 
silica gel 60, 1 mm film thickness, F254). These PLC plates were developed simultaneously in 100% 
EtOAc seven times, to yield three bands (PP0_1-3). The compound was removed from each of these 
bands by scraping off the silica and washing with 20% MeOH in EtOAc. The component of interest 
(compound 23) was noted by TLC analysis to be the sole constituent of PP0_2 (178.5 mg). 
11.1.1.6 PP1 
S1 (297.7 mg) was acquired by trituration of P1_10-12 with MeOH. 100 mg of S1 was dissolved in 
a minimum amount of MeOH (some H2O added to assist), and was streaked onto a PLC plate (Merck, 
silica gel 60, 1 mm film thickness, F254). After drying, the plate was developed once in EtOAc:MeOH, 
H2O (85:10:5), showing two clearly visible bands (PP1_1-2). The top band (PP1_1, 44.8 mg) 
produced a 1H NMR spectrum correlating to that of CV3 (Appendix A) and was further processed on 
C3. The lower band (PP1_2, 42.4 mg) correlated by TLC to lycorine, and was kept aside. 
11.1.1.7 C3 
21 g silica (Merck, silica 60, 230-400 mesh) was equilibrated in 100% DCM and poured into a glass 
column (1 cm diameter). PP1_1 was dissolved in DCM and wet loaded onto the surface of C3.  
C3 was eluted using the following solvent systems: 5% MeOH/DCM (1000 mL), 10% MeOH/DCM 
(750 mL).  
20 mL fractions were collected and grouped based on TLC analysis into three fraction groups (C3_1-
3). Only fractions showing a single spot under both UV and Dragendorff’s reagent were placed 
grouped together (C3_2, 20.8 mg), and the sample was labelled CV3.  
11.1.1.8 C3.1 
This column was carried out with the aim of purifying the CV3 present in the mother liquor of S1 
(P1_10-12 remaining after trituration, ca. 800 mg).  
100 g silica (Merck, silica 60, 230-400 mesh) was equilibrated in 100% EtOAc and poured into a 
glass column (4 cm diameter). The remaining P1_10-12 was loaded onto silica, and C3.1 was eluted 
with: 100% EtOAc (2500 mL), 1% MeOH/EtOAc (1500 mL), 2% MeOH/EtOAc (2250 mL), 4% 
MeOH/EtOAc (2000 mL), 10% MeOH/EtOAc (1750 mL), EtOAc:MeOH:H2O (85:10:5), 100% 
MeOH (750 mL).  
20 mL fractions were collected and combined into five fraction groups (C3.1_1-5) based on TLC 
profile. C3.1_4 (658 mg) contained CV3 as the major component (though this was impure – TLC 





180 g silica (Merck, silica 60, 230-400 mesh) was equilibrated in 100% DCM and poured into a glass 
column (4 cm diameter). P1_13-26 (ca. 760 mg) was loaded onto silica and added to the top of C4.  
C4 was eluted with: 100% DCM (500 mL), 0.5% MeOH/DCM (500 mL), 1% MeOH/DCM (500 
mL), 1.5% MeOH/DCM (500 mL), 2% MeOH/DCM (500 mL), 2.5% MeOH/DCM (250 mL), 3% 
MeOH/DCM (250 mL), 4% MeOH/DCM (250 mL), 5% MeOH/DCM (250 mL), 6% MeOH/DCM 
(250 mL), 7% MeOH/DCM (250 mL), 8% MeOH/DCM (250 mL), 10% MeOH/DCM (250 mL), 
12% MeOH/DCM (250 mL), 15% MeOH/DCM (1750 mL), 20% MeOH/DCM (1000 mL), 30% 
MeOH/DCM (1250 mL), 50% MeOH/DCM (1000 mL). 100% MeOH (750 mL), 10% acetic acid in 
MeOH (250 mL).  
15 mL fractions were collected and, based on TLC analysis, were combined into 26 fraction groups 
(C4_1-26).  
11.1.1.10 PP2 
C4_12-16 (211 mg) was dissolved in MeOH and streaked onto a PLC plate (Merck, silica gel 60, 2 
mm film thickness, F254). PP2 was developed three times in EtOAc:MeOH:H2O (85:10:5), resulting 
in the visualisation of four bands (PP2_1-4). These bands were scraped off and washed with 20% 
MeOH in EtOAc to isolate the compounds. PP2_2 was processed further on PP3, and PP2_3-4 was 
processed further on PP4.  
11.1.1.11 PP3 
PP2_2 (66.7 mg) was dissolved in MeOH and streaked onto a PLC plate (Merck, silica gel 60, 1 mm 
film thickness, F254). PP3 was developed once in EtOAc:MeOH:H2O (85:10:5), resulting in five 
bands (PP3_1-5). PP3_3 (45.5 mg) was the most intense band, with the others showing little response 
to UV light (254 nm). PP3_3 was identified as compound 26. Masses of the other bands were not 
recorded.  
11.1.1.12 PP4 
PP2_3-4 (53.4 mg) was dissolved in MeOH and streaked onto a PLC plate (Merck, silica gel 60, 1 
mm film thickness, F254). PP4 was developed three times in CHCl3:EtOAc:MeOH (2:2:1), resulting 
in three bands (PP4_1-3). PP4_2 was processed further on C5.  
11.1.1.13 C5 
10 g of alumina (Sigma Aldrich, active neutral, 150 mesh) was equilibrated in 100% EtOAc, and 




C5 was eluted with: 100% EtOAc (750 mL – until all of compound of interest had eluted), 1% 
MeOH/EtOAc (25 mL), 2%MeOH/EtOAc (25 mL), 4% MeOH/EtOAc (25 mL), 6% MeOH/EtOAc 
(25 mL), 8% MeOH/EtOAc (25mL), 10% MeOH/EtOAc (150 mL), 15% MeOH/EtOAc (125 mL), 
20% MeOH/EtOAc (100 mL), 100% MeOH (350 mL).  
7 mL fractions were collected and grouped according to TLC profile into two fraction groups. C5_1 
contained pure compound 27 (6.4 mg), and C5_2 contained all compounds which eluted after that.  
11.1.2 HPLC-MS/MS of CVAlk.EXT 
Sample preparation: A small quantity of the sample (ca. 2 mg) was dissolved in 1 mL of analytical 
grade MeOH and filtered through a 0.2 µm syringe filter. Any necessary concentration corrections 
were made by dilution before analysis.  
UPLC conditions: The UPLC system consisted of ACQUITY Ultra High-Performance LC system 
(Waters, Milford, MA, USA) and software MassLynx v4.1. Separation of Amaryllidaceae alkaloids 
was carried out on a Waters HSS T3 column, 2.1x100mm. Solvent A: Water (0.1% formic acid), 
Solvent B: Acetonitrile (0.1% formic acid). Gradient (linear programme) as follows: 0.0-0.50 min, 
90%; 2.00 min, 70%; 5.50 min, 40%; 6.60 min, 10%; 6.70-10.00 min, 90% of A. Flow rate was 0.380 
mL/min and injection volume was 1 µL. 
ESI-MS/MS conditions: MS/MS analysis was performed on a Synapt-G2 High Definition Mass 
Spectrometer equipped with an ESI source (Waters, Milford, MA, USA) and Masslynx v4.1. 
Parameters as follows: polarity ES+ , capillary voltage 2.5 kV, sampling cone 15 V, extraction cone 
4V, source temp. 120 °C, cone gas flow 50 L/h, desolvation temp. 275 °C, desolvation gas flow 650 
L/h, Helium call gas flow 180 mL/min, trap gas flow 0.4 mL/min, trap collision energy 15 eV, ion 
energy 1.8 eV. 
11.2 Crinum paludosum 
11.2.1 HPLC-MS/MS of CPAlk.EXT 
Sample preparation: A small quantity of the sample (ca. 2 mg) was dissolved in 1 mL of analytical 
grade MeOH and filtered through a 0.2 µm syringe filter. Any necessary concentration corrections 
were made by dilution before analysis.  
UPLC conditions: The UPLC system consisted of ACQUITY Ultra High-Performance LC system 
(Waters, Milford, MA, USA) and software MassLynx v4.1. Separation of Amaryllidaceae alkaloids 
was carried out on a Waters HSS T3 column, 2.1x100mm. Solvent A: Water (0.1% formic acid), 




90%; 2.00 min, 70%; 5.50 min, 40%; 6.60 min, 10%; 6.70-10.00 min, 90% of A. Flow rate was 0.380 
mL/min and injection volume was 1 µL. 
ESI-MS/MS conditions: MS/MS analysis was performed on a Synapt-G2 High Definition Mass 
Spectrometer equipped with an ESI probe (Waters, Milford, MA, USA) and Masslynx v4.1. 
Parameters as follows: polarity ES+ , capillary voltage 2.5 kV, sampling cone 15 V, extraction cone 
4V, source temp. 120 °C, cone gas flow 50 L/h, desolvation temp. 275 °C, desolvation gas flow 650 
L/h, Helium call gas flow 180 mL/min, trap gas flow 0.4 mL/min, trap collision energy 15 eV, ion 
energy 1.8 eV. 
11.3 Higginsianins A and B 
11.3.1 Higginsianin A 39 
11.3.1.1 Acetylation of Higginsianin A 39 
To a solution of 39 (50 mg, 1.17×10-4 mols) in pyridine (5 mL) was added acetic anhydride (5 mL) 
while stirring. The reaction mixture was stirred for 24 hrs, then poured over ice to precipitate the 
acetate product (22-O-acetylhigginsianin A 39a, 45 mg, 81.9%), which was removed by filtration. 
Purification by gravity column was carried out on silica gel (Merck, silica 60, 230-400 mesh) using 
a gradient of EtOAc in hexane. Comparison of the 1H NMR spectrum to that reported in literature 
confirmed the identity.73 
11.3.1.2 Reaction of 39a with maleic anhydride 
To a solution of 39a (20 mg, 4.27×10-5 mols) in pre-distilled benzene (ca. 10 mL) was added maleic 
anhydride (1.1 eq.), and the reaction mixture was left under reflux for 5 hrs. TLC showed starting 
material, and so additional 5 mg of maleic anhydride was added. No change noted on TLC after an 
additional hour, and so a catalytic amount (ca. 1 mg) of AlCl3 was added. After an additional hour, 
no change was noted, and the reaction was stopped and starting material recovered by gravity column.  
11.3.1.3 Reaction of 39a with m-CPBA 
Solid reagents (39a, 20 mg, 4.27×10-5 mols; m-CPBA, 1 eq.) were added to DCM (ca. 10 mL) and 
stirred for 5 hrs at −10 °C. No reaction occurred based on TLC analysis, and the reaction mixture was 
concentrated under reduced pressure to ca. 2 mL, and stirred at room temperature (RT) for a further 
72 hrs. No reaction occurred after this time, and the reaction was heated to 30 °C and stirred for a 
further 45 hrs, after which no reaction had occurred, and the reaction was stopped. Starting material 





11.3.1.4 Reductive hydrogenation of 39 with Pd/C 
Solid reagents (39, 20 mg, 4.69×10-5 mols; Pd/C (10% Pd), cat.) were added to dry MeOH (3 mL), 
and stirred at RT under positive H2 pressure for ca. 6 hrs, after which the reaction mixture was filtered 
and the solvent removed under reduced pressure. The result was a mixture of products which were 
not characterised.  
11.3.1.5 Reaction of 39 with NBS 
Solid reagents (39, 20 mg, 4.69×10-5 mols; NBS, 8.3 mg, 1 eq.; AIBN, cat.) were placed in the bottom 
of a reaction vessel, and 1 mL of dry DCM was added to this. The reaction mixture was kept in the 
dark and stirred for 7 hrs at RT. The reaction mixture was then washed with sodium bicarbonate 
solution, the organic layer dried with MgSO4, and the solvent removed under reduced pressure 
(exposure to light was minimised where possible by covering vessels in tinfoil). NMR spectroscopic 
sample was wrapped in tinfoil and kept in the fridge (4 °C) before analysis. The result was a mixture 
of products as discussed above (see Appendix B for crude NMR spectra).  
11.3.2 Higginsianin B 40 
11.3.2.1 Acetylation of Higginsianin B 40 
Higginsianin B 40 (50 mg, 1.17×10-4 mols) was dissolved in CHCl3 (2 mL) and pyridine (0.5 mL) 
mixture (CHCl3 did not adequately dissolve 40). This was added to a reaction vessel which had been 
purged with N2, followed by acetic anhydride (0.5 mL). The reaction mixture was stirred under N2 
atmosphere at RT for 40 hrs. The reaction mixture was then diluted with DCM, washed with water 
(3×20 mL), 1 M HCl (3×20 mL), and finally brine (1×20 mL), after which the organic layer was dried 
with MgSO4 and the solvent removed under reduced pressure. The resulting products were separated 
by TLC (2 plates, Merck, silica gel 60, 0.25 mm film thickness, F254, 20×20 cm), developed three 
times in 10% EtOAc/hexane. Please see Appendix B for 1H NMR and 13C NMR spectra of the two 
products. Though full characterisation of the products was not carried out, evidence in the 1H NMR 
spectrum showed the production of the expected products, as discussed in chapter 8.2.2.  
11.3.2.2 Reaction of 40 with PCC 
PCC (15 mg, 6.96×10-5 mols) was crushed with a spatula tip of silica in a mortar and pestle. This, 
along with 40 (20 mg, 4.67×10-5 mols), was added to a reaction vessel, which was purged with N2. 
Dry DCM (3 mL) was then added under positive N2 pressure. The reaction vessel was then sealed 
and left to stir for 3.5 hrs at RT. Reaction was stopped by filtration through celite to remove all solid 
reagents, and the solvent was removed from the filtrate. The result was a mixture of compounds which 




11.3.2.3 Ozonolysis of 40 
40 (30 mg, 7.0×10-5 mols) was added to dry MeOH (5 mL) in a 100 mL round bottom flask. Dry 
DCM (20 mL) was then added, along with a stir bar. This mixture was placed in a slurry of acetone 
and dry ice (−78 °C) while stirring. Once the mixture had been left to cool to this temperature, oxygen 
was bubbled through the mixture, followed by ozone (charge on ozone generator turned on to initiate 
ozone flow). Ozone was bubbled through for 15 min, to allow saturation (solution went blue after ca. 
5 min). Following this, oxygen was once more bubbled through until the solution was clear. Positive 
N2 pressure was then quickly applied (upon removal of O2 supply), and the cold bath was removed. 
Me2S (4 eq.) was then added under positive N2 pressure, and the reaction mixture was left to cool to 
RT while stirring. The solvent was then removed under reduced pressure. The result was a mixture 
of products which were not characterised. 
11.3.2.4 Reductive hydrogenation of 40 with Pd/C 
Solid reagents (40, 20 mg, 4.67×10-5 mols; Pd/C (10% Pd), cat.) were added to dry MeOH (3 mL), 
and stirred at RT under positive H2 pressure for ca. 72 hrs, after which the reaction mixture was 
filtered and the solvent removed under reduced pressure. The result was a single spot on TLC, though 
crude 1H NMR spectroscopy suggested two possible products, which degraded in CDCl3 after crude 
NMR spectroscopic analysis (see Appendix B for crude NMR spectra).  
11.3.2.5 Reaction of 40 with m-CPBA 
Solid reagents (40, 20 mg, 4.67×10-5 mols; m-CPBA, 2.4 eq.) were added to a reaction vessel, which 
was then purged with N2. Dry DCM (2 mL) was then added under positive N2 pressure, the vessel 
was sealed, and the mixture was stirred at RT for 72 hrs. Work-up was carried out by addition of 
DCM (ca. 15 mL) to the reaction mixture, followed by washing with saturated sodium bicarbonate 
solution, drying of the organic layer with MgSO4, and removal of the solvent under reduced pressure 
to obtain the crude product. This showed a single spot on TLC, and was subjected to 1H NMR analysis 
(see Appendix B for crude NMR spectra), with the intention of purification and full characterisation, 
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A Appendix – Crinum variabile 
A.1 Tree Diagram – Crinum variabile 
 



























A.2 Lycorine 19 
 
Figure A.2.1 - The numbered chemical structure of lycorine 19. 
 





Figure A.2.3 - 13C spectrum of 19 
 





Figure A.2.5 - HSQC spectrum of 19. 
 




A.3 1,2-O,O-diacetyllycorine 21 
 
Figure A.3.1 - The numbered chemical structure of 21. 
 
Figure A.3.2 - 1H spectrum of 21. 
 





Figure A.3.4 - HSQC spectrum of 21. 
 





Figure A.3.6 - COSY spectrum of 21. 




A.4 2-O-acetyllycorine 22 
 
 
Figure A.4.1 - The numbered structure of 22 
 
 






Figure A.4.3 - 13C spectrum of 22 
 
 






Figure A.4.5 - HMBC spectrum of 22 
 
 










A.5 1-O-acetyllycorine 23 
 
 
Figure A.5.1 - Numbered chemical structure of 23. 
 
Figure A.5.2 - 1H spectrum of 23. 
  





Figure A.5.4 - HSQC spectrum of 23. 
 





Figure A.5.6 - COSY spectrum of 23. 
 








A.6 Haemanthidine and 6-epihaemanthidine 24, 25 
 
Figure A.6.1 - Chemical structures of 24 and 25. 
 





Figure A.6.3 - 13C NMR spectrum of 24 and 25. 
  





Figure A.6.5 - Elemental composition analysis of CV3 peak. 
 




A.7 Bulbispermine 26 
 
Figure A.7.1 - The numbered chemical structure of bulbispermine 26. 
 
Figure A.7.2 - 1H NMR spectrum of 26. 
 





Figure A.7.4 - HSQC spectrum of 26. Using the appropriate phasing during processing, carbon atoms with 2 protons attached can be 















A.8 Criwelline 27 
 
Figure A.8.1 - The numbered chemical structure of 27. 
 





Figure A.8.3 - 13C NMR spectrum of 27. 
 
Figure A.8.4 - HSQC spectrum of 27. Using the appropriate phasing during processing, carbon atoms with 2 protons attached can be 










































solvent below H2O 
Solvent bubbles “fall” 





Solvent bubbles rise 
through aqueous layer 
Figure A.9.1 - The operation of a continuous  liquid/liquid extraction apparatus. Operation with more dense solvents such as DCM shown on the left, and 




B Appendix – Higginsianins A and B 
B.1 Higginsianin A 39 
 
Figure B.1.1 - Numbered chemical structure of higginsianin A 39. 
 




B.1.1 22-O-acetylhigginsianin A 39a 
 
Figure B.1.3 – Acetylation of 39 to 22-O-acetylhigginsianin A 39a.  
 
Figure B.1.4 - 1H NMR spectrum of 39a. 
 




B.1.2 NBS bromination of 39 
 
Figure B.1.6 - 1H NMR of product mixture from bromination of 39 with NBS. 
 










B.2 Higginsianin B 40 
 
Figure B.2.1 - Numbered chemical structure of higginsianin B 40. 
 





Figure B.2.3 - 13C NMR spectrum of 40 as acquired from corresponding research group. 
 
B.2.1 Acetylation of 40 
 





Figure B.2.5 - 1H NMR spectrum of 40a. 
 





Figure B.2.7 - 1H NMR spectrum of 40b. 
 





Figure B.2.9 - 1H NMR spectra of 40, 40a and 40b stacked. 
 
Figure B.2.10 - Elemental composition analysis window for 40a. 
 




B.2.2 Reductive hydrogenation of 40 to 40c/40d. 
 
Figure B.2.12 - Scheme for the reaction of 40 with Pd/C. 
 





Figure B.2.14 - Stacked spectra of 40 and crude 40c and 40d. 
B.2.3 Epoxidation of 40 to 40e 
 









Figure B.2.16 - 1H NMR spectrum of crude 40e. 
 
Figure B.2.17 - Stacked 1H NMR spectra of 40 and crude 40e. 
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